US20210177620A1 - Porous composite biomaterials and related methods - Google Patents

Porous composite biomaterials and related methods Download PDF

Info

Publication number
US20210177620A1
US20210177620A1 US17/180,935 US202117180935A US2021177620A1 US 20210177620 A1 US20210177620 A1 US 20210177620A1 US 202117180935 A US202117180935 A US 202117180935A US 2021177620 A1 US2021177620 A1 US 2021177620A1
Authority
US
United States
Prior art keywords
polymer
particles
composite material
scaffold
reinforcement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/180,935
Inventor
Ryan K. Roeder
Gabriel L. Converse
Stephen M. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Happe Spine LLC
Original Assignee
Happe Spine LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Happe Spine LLC filed Critical Happe Spine LLC
Priority to US17/180,935 priority Critical patent/US20210177620A1/en
Publication of US20210177620A1 publication Critical patent/US20210177620A1/en
Priority to US17/519,336 priority patent/US20220062004A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2/44Joints for the spine, e.g. vertebrae, spinal discs
    • A61F2/4455Joints for the spine, e.g. vertebrae, spinal discs for the fusion of spinal bodies, e.g. intervertebral fusion of adjacent spinal bodies, e.g. fusion cages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/28Bones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2/44Joints for the spine, e.g. vertebrae, spinal discs
    • A61F2/4455Joints for the spine, e.g. vertebrae, spinal discs for the fusion of spinal bodies, e.g. intervertebral fusion of adjacent spinal bodies, e.g. fusion cages
    • A61F2/4465Joints for the spine, e.g. vertebrae, spinal discs for the fusion of spinal bodies, e.g. intervertebral fusion of adjacent spinal bodies, e.g. fusion cages having a circular or kidney shaped cross-section substantially perpendicular to the axis of the spine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02Inorganic materials
    • A61L27/12Phosphorus-containing materials, e.g. apatite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/18Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/26Mixtures of macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/46Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56Porous materials, e.g. foams or sponges
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B29WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29CSHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C67/00Shaping techniques not covered by groups B29C39/00 - B29C65/00, B29C70/00 or B29C73/00
    • B29C67/20Shaping techniques not covered by groups B29C39/00 - B29C65/00, B29C70/00 or B29C73/00 for porous or cellular articles, e.g. of foam plastics, coarse-pored
    • B29C67/202Shaping techniques not covered by groups B29C39/00 - B29C65/00, B29C70/00 or B29C73/00 for porous or cellular articles, e.g. of foam plastics, coarse-pored comprising elimination of a solid or a liquid ingredient
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J9/00Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
    • C08J9/0066Use of inorganic compounding ingredients
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J9/00Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
    • C08J9/28Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08JWORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J9/00Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
    • C08J9/36After-treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2/3094Designing or manufacturing processes
    • A61F2/30965Reinforcing the prosthesis by embedding particles or fibres during moulding or dipping
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/28Bones
    • A61F2002/2817Bone stimulation by chemical reactions or by osteogenic or biological products for enhancing ossification, e.g. by bone morphogenetic or morphogenic proteins [BMP] or by transforming growth factors [TGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/28Bones
    • A61F2002/2835Bone graft implants for filling a bony defect or an endoprosthesis cavity, e.g. by synthetic material or biological material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/30004Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis
    • A61F2002/30006Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis differing in density or specific weight
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/30004Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis
    • A61F2002/30011Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis differing in porosity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/30004Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis
    • A61F2002/30032Material related properties of the prosthesis or of a coating on the prosthesis the prosthesis being made from materials having different values of a given property at different locations within the same prosthesis differing in absorbability or resorbability, i.e. in absorption or resorption time
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/3006Properties of materials and coating materials
    • A61F2002/30062(bio)absorbable, biodegradable, bioerodable, (bio)resorbable, resorptive
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30003Material related properties of the prosthesis or of a coating on the prosthesis
    • A61F2002/3006Properties of materials and coating materials
    • A61F2002/30065Properties of materials and coating materials thermoplastic, i.e. softening or fusing when heated, and hardening and becoming rigid again when cooled
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30108Shapes
    • A61F2002/30199Three-dimensional shapes
    • A61F2002/30224Three-dimensional shapes cylindrical
    • A61F2002/30225Flat cylinders, i.e. discs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30108Shapes
    • A61F2002/30199Three-dimensional shapes
    • A61F2002/30224Three-dimensional shapes cylindrical
    • A61F2002/30235Three-dimensional shapes cylindrical tubular, e.g. sleeves
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2002/30001Additional features of subject-matter classified in A61F2/28, A61F2/30 and subgroups thereof
    • A61F2002/30621Features concerning the anatomical functioning or articulation of the prosthetic joint
    • A61F2002/30622Implant for fusing a joint or bone material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2/30767Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
    • A61F2/30771Special external or bone-contacting surface, e.g. coating for improving bone ingrowth applied in original prostheses, e.g. holes or grooves
    • A61F2002/30904Special external or bone-contacting surface, e.g. coating for improving bone ingrowth applied in original prostheses, e.g. holes or grooves serrated profile, i.e. saw-toothed
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2/30767Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
    • A61F2002/3092Special external or bone-contacting surface, e.g. coating for improving bone ingrowth having an open-celled or open-pored structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/30Joints
    • A61F2/3094Designing or manufacturing processes
    • A61F2/30942Designing or manufacturing processes for designing or making customized prostheses, e.g. using templates, CT or NMR scans, finite-element analysis or CAD-CAM techniques
    • A61F2002/30957Designing or manufacturing processes for designing or making customized prostheses, e.g. using templates, CT or NMR scans, finite-element analysis or CAD-CAM techniques using a positive or a negative model, e.g. moulds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0004Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0071Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof thermoplastic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0063Three-dimensional shapes
    • A61F2230/0069Three-dimensional shapes cylindrical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/0015Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in density or specific weight
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/0018Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in elasticity, stiffness or compressibility
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/0023Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in porosity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0014Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
    • A61F2250/003Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in adsorbability or resorbability, i.e. in adsorption or resorption time
    • A61F2250/0031Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in adsorbability or resorbability, i.e. in adsorption or resorption time made from both resorbable and non-resorbable prosthetic parts, e.g. adjacent parts

Definitions

  • the present disclosure relates generally to composite biomaterials and more particularly to porous composite biomaterials and related methods.
  • Natural bone grafts such as autogenous bone grafts (autografts) are commonly used in procedures for repairing or replacing bone defects because they provide good structural support and osteoinductivity. Natural bone grafts involve removing or harvesting tissue from another part of a host's body (e.g., typically from the iliac crest, hip, ribs, etc.) and implanting the harvested tissue in the defect site. Not only do these grafts require an added surgical procedure needed to harvest the bone tissue, these grafts have limitations, including for example, transplant site morbidity.
  • One alternative to autografts is allografts, which involve removing and transplanting tissue from another human (e.g., from bone banks that harvest bone tissue from cadavers) to the defect site.
  • DBM Demineralized bone matrix
  • Synthetic bone substitute materials have been researched in the treatment of diseased bone (e.g., osteoporosis), injured bone (e.g., fractures), or other bone defects in lieu of natural bone grafts. Synthetic bone substitutes are viable alternatives to the more traditional methods described above. However, synthetic substitute materials used to repair diseased bones and joints should function or perform biologically and mechanically (i.e., as the structural support role of the bone itself) by, for example, mimicking the density and overall physical structure of natural bone to provide a framework for ingrowth of new tissue.
  • One type or application of a synthetic bone substitute is a scaffold, which provides support for bone-producing cells.
  • Scaffolds may be biodegradable, which degrade in vivo, or they may be non-biodegradable to provide permanent implant fixation (e.g., spinal fusion cages).
  • scaffolds are typically biocompatible, and some may be bioactive, bioresorbable, osteoconductive, and/or osteoinductive. The shapability, deliverability, cost, and ability to match the mechanical properties of the surrounding host tissue are other factors that vary among different types of scaffolds and other bone substitutes.
  • FIG. 1A is a perspective view of an example porous composite material described herein.
  • FIG. 1B is a cross-sectional view of a portion of the example porous composite material of FIG. 1A .
  • FIG. 2A-2C are scanning electron micrographs of a portion of the example porous composite material shown in increasing magnification.
  • FIGS. 3 is graphical representation of the elastic modulus of example apatite reinforced polymer composites versus the reinforcement volume fraction.
  • FIG. 4 shows scanning electron micrograph of a portion of the surface of an example composite material reinforced with calcium phosphate whiskers embedded within and exposed on the surface, and schematically showing the orientation of the whiskers relative to the loading direction of the material or scaffold strut.
  • FIG. 5A is a schematic illustration of a known spinal fusion cage inserted between spinal vertebrae.
  • FIG. 5B illustrates the example known spinal fusion cage of FIG. 5A .
  • FIG. 6 illustrates another example scaffold described herein.
  • FIG. 7 illustrates yet another example scaffold described herein.
  • FIG. 8 is a flow diagram illustrating an example process of creating an example composite material apparatus described herein.
  • the example methods, apparatus, and materials described herein provide a biocompatible, bioactive synthetic porous composite for use as synthetic bone substitute materials.
  • the synthetic composite may provide a synthetic porous scaffold for use an orthopedic implant and/or be injectable via percutaneous or surgical injection to cure in vivo. Because the example composite material is used to form a scaffold or matrix that is used in an implantable device, the descriptions of one or more of these structures may also describe one or more of the other structures.
  • the synthetic porous composites are tailored to mimic biological and mechanical properties of bone tissue for implant fixation, synthetic bone graft substitutes, tissue engineering scaffolds, interbody spinal fusion, or other orthopedic applications.
  • An example porous composite material described herein reduces subsidence and/or bone resorption resulting from mechanical mismatch problems between a synthetic scaffold of an implant device and the peri-implant tissue. Additionally, porosity and/or the pore sizes of the example synthetic composite are tailorable to specific applications to effectively promote the vascularization and growth of bone in the pores and/or void spaces of the example scaffolds, thereby improving bonding between the scaffolds and peri-implant tissue.
  • the example composite material or scaffolds are synthesized or made through a process that enables reinforcement particles to be integrally formed with or embedded within polymer matrices.
  • the polymer matrices embedded with the reinforcement material provide improved material properties (e.g., stiffness, fatigue strength, and toughness).
  • the reinforcement particles are also exposed on a surface of the matrices, which promotes bioactivity and/or bioresorption.
  • the process provides flexibility to tailor the level of reinforcement particles and porosity for a desired application.
  • a porogen material may be used to vary the porosity, while the pore size is tailored by, for example, sieving the porogen to a desired size.
  • the mechanical properties (e.g., stiffness, strength, toughness, etc.) of the example scaffold of the implant device may be tailored to match those of the adjacent peri-implant bone tissue to reduce mechanical mismatch problems. Reducing mechanical mismatch provides a decreased risk of subsidence, stress shielding, bone resorption, and/or subsequent failure of adjacent peri-implant bone tissue. Additionally, the example scaffold of the implant device may include a significantly high porosity to promote bone ingrowth, while exhibiting significantly higher effective mechanical properties such as, for example, the mechanical properties of trabecular bone.
  • the example composite material includes a continuous porous biocompatible matrix having a thermoplastic polymer matrix reinforced with anisometric calcium phosphate particles.
  • a composite material includes a polyetheretherketone (PEEK) or a polyetherketoneketone (PEKK) matrix reinforced with various volume fractions of hydroxyapatite (HA) whiskers (e.g., 20 or 40 volume percent), wherein the matrix is approximately between 70% and 90% porous.
  • PEEK polyetheretherketone
  • PEKK polyetherketoneketone
  • HA hydroxyapatite
  • the porous matrix includes a biocompatible, microporous polymer cage reinforced with anisometric calcium phosphate particles and bone morphogenic protein (BMP) such as, for example, rhBMP-2, which can be dispersed or accommodated by the void spaces and/or pores of the example porous scaffold and/or exposed on the surface of the example porous scaffold. Additionally, the BMP binds to the calcium phosphate further localizing the BMP to the surface of the scaffold or matrix.
  • BMP bone morphogenic protein
  • the example composite materials described herein may be used for applications such as, for example, synthetic bone graft substitutes, bone ingrowth surfaces applied to existing implants, tissue engineering scaffolds, interbody spinal fusion cages, etc.
  • carrier materials e.g., collagen, hydrogels, etc.
  • growth factors such as BMP
  • a femur includes a cortical bone that has a relative porosity on the order of about 5-15%, and a trabecular bone that has a porosity on the order of about 75-95%. Due to the highly significant porosity differences, the trabecular bone exhibits significantly lower effective mechanical properties compared to the cortical bone. Therefore, depending on the application, synthetic composite materials for use as scaffolds and/or spinal fusion cages or other implant devices should possess the mechanical properties exhibited by the cortical bone or the trabecular bone, but must also have effective porosity to promote bone growth.
  • the example scaffold of the implant device described herein may be tailored to substantially match or mimic the mechanical properties (e.g., stiffness, strength, toughness, etc.) of the adjacent and/or substituted bone tissue.
  • the mechanical properties e.g., stiffness, strength, toughness, etc.
  • Several factors may be varied during the synthesis of the composite material and scaffold of the implant device to tailor the mechanical properties including the calcium phosphate reinforcement volume fraction, aspect ratio, size and orientation; the polymer; and the size, volume fraction, shape and directionality of the void space and/or porosity. Tailoring the mechanical properties of the scaffold reduces the likelihood of mechanical mismatch leading to a decreased risk of subsidence, stress shielding, bone resorption and/or subsequent failure of adjacent vertebrae.
  • FIG. 1A illustrates the example synthetic porous composite material 100 described herein.
  • FIG. 1B is a cross-sectional view of a portion of the example porous composite material 100 of FIG. 1A .
  • the example synthetic composite material 100 provides a synthetic porous scaffold 101 for use or in as an orthopedic implant.
  • the example synthetic porous composite material 100 includes a porous thermoplastic polymer (e.g., a PEEK polymer) matrix 102 having anisometric calcium phosphate reinforcement particles 104 integrally formed or embedded with the matrix 102 and/or exposed on a surface of the matrix.
  • a porous thermoplastic polymer e.g., a PEEK polymer
  • the porous polymer matrix 102 includes a substantially continuous porosity and a plurality of pores 106 to enable bone ingrowth into the porous matrix 102 .
  • the matrix 102 is substantially continuously interconnected via a plurality of struts 108 .
  • At least one of the plurality of struts 108 may be a load-bearing strut.
  • FIGS. 2A-2C are scanning electron micrographs showing increasing magnification of a portion of an example scaffold 200 with struts 202 .
  • the example scaffold 200 is a PEEK scaffold reinforced with 40% by volume HA whiskers 204 .
  • FIG. 2A illustrates the architecture or matrix 206 of the scaffold 200 and FIG. 2B illustrates an enlarged portion of the struts 202 .
  • the HA whiskers 204 are integrally formed and/or embedded within the matrix 206 of the scaffold 200 for reinforcement.
  • the HA whiskers 204 are also exposed on a surface 208 of the matrix of the scaffold 200 for bioactivity and/or bioresorption, as noted above.
  • the HA whiskers 204 are aligned in a sheet texture and are exposed on the surface 208 of the struts 202 .
  • thermoplastic polymer of the example scaffolds described herein may be a biodegradable polymer for synthetic bone graft substitute applications, or nonbiodegradable for implant fixation applications.
  • the thermoplastic polymer includes a continuous matrix of a composite material and is biocompatible and/or bioresorbable as described above.
  • the polymer may be a radiolucent polymer, bioresorbable (i.e., a material capable of being resorbed by a patient under normal physiological conditions) and/or non-bioresorbable, as desired.
  • the thermoplastic polymer matrix may include a polymer suitable for injection via percutaneous or surgical injection so that the composite material 100 cures in vivo.
  • Suitable non-resorbable polymers include, without limitation, polyaryletherketone (PAEK), polyetheretherketone (PEEK), polyetherketonekteone (PEKK), polyetherketone (PEK), polyethylene, high density polyethylene (HDPE), ultra-high molecular weight polyethylene (UHMWPE), low density polyethylene (LDPE), polyethylene oxide (PEO), polyurethane, polypropylene, polypropylene oxide (PPO), polysulfone, polypropylene, copolymers thereof, and blends thereof.
  • PAEK polyaryletherketone
  • PEEK polyetheretherketone
  • PEKK polyetherketonekteone
  • PEK polyetherketone
  • PEK polyethylene, high density polyethylene (HDPE), ultra-high molecular weight polyethylene (UHMWPE), low density polyethylene (LDPE), polyethylene oxide (PEO), polyurethane, polypropylene, polypropylene oxide (PPO), polysulfone, polypropylene, copolymers thereof
  • Suitable bioresorbable polymers include, without limitation, poly(DL-lactide) (PDLA), poly(L-lactide) (PLLA), poly(glycolide) (PGA), poly( ⁇ -caprolactone) (PCL), poly(dioxanone) (PDO), poly(glyconate), poly(hydroxybutyrate) (PHB), poly(hydroxyvalerate (PHV), poly(orthoesters), poly(carboxylates), poly(propylene fumarate), poly(phosphates), poly(carbonates), poly(anhydrides), poly(iminocarbonates), poly(phosphazenes), copolymers thereof, and blends thereof.
  • PDLA poly(DL-lactide)
  • PLLA poly(L-lactide)
  • PGA poly(glycolide)
  • PCL poly( ⁇ -caprolactone)
  • PDO poly(dioxanone)
  • PDO poly(glyconate), poly(hydroxybutyrate) (PH
  • Suitable polymers that are injectable via percutaneous or surgical injection that cure in vivo include, without limitation, polymethylmethacrylate (PMMA), and other polyacrylics from monomers such as bisphenol a hydroxypropylmethacrylate (bis-GMA) and/or tri(ethylene glycol) dimethacrylate (TEG-DMA).
  • PMMA polymethylmethacrylate
  • bis-GMA bisphenol a hydroxypropylmethacrylate
  • TEG-DMA tri(ethylene glycol) dimethacrylate
  • synthetic substitute composite materials made of polymers satisfy the functional criteria of an implantable device because they are, for example, formable and inexpensive, polymers alone lack biological efficacy to promote bone growth and/or may lack requisite mechanical properties to support load levels.
  • the polymers are reinforced with calcium phosphates.
  • the aspect ratio, size, volume fraction and degree of preferred orientation of the calcium phosphate particles 104 may be tailored for the desired material properties and implant performance. For example, consider the information presented in FIG. 3 , which is a graphical illustration of the elastic modulus of HA whisker and powder reinforced polymer composite materials versus the volume fraction percentage of the apatite calcium phosphates that is mixed with the polymer matrix.
  • the shaded areas of FIG. 3 show approximate regions for the given mechanical property of the human cortical bone tissue.
  • the elastic modulus of the composite materials increases with increasing HA content.
  • increasing the level of HA reinforcement in polymer composites increases cellular activity during osteointegration.
  • the calcium phosphate reinforcement particles 104 may be in the form of single crystals or dense polycrystals but are at least in some portion anisometric.
  • “Anisometric” refers to any particle morphology (shape) that is not equiaxed (e.g., spherical), such as whiskers, plates, fibers, etc.
  • Anisometric particles are usually characterized by an aspect ratio.
  • HA single crystals are characterized by the ratio of dimensions in the c- and a-axes of the hexagonal crystal structure.
  • the anisometric particles in the present disclosure have an aspect ratio greater than 1.
  • the mean aspect ratio of the reinforcement particles is from about 1 to about 100.
  • the reinforcement particles can be provided in an amount of from about 1% by volume of the composite biomaterial to about 60% by volume, and for example, from about 20% by volume of the composite to about 50% by volume.
  • the calcium phosphate reinforcements particles 104 may be oriented in bulk or near the surface of the polymer matrix 102 to provide directional properties, if desired. For example, if the reinforcement particles 104 are predominately aligned within the matrix 102 the morphological alignment of the particles 104 provides anisotropy for the overall composite 100 , which can be tailored to be similar to the anisotropic mechanical properties of bone tissues.
  • FIG. 4 shows a micrograph of anisometric calcium phosphate reinforcement 400 on the surface of a dense composite polymer matrix 402 . Also shown in FIG. 4 is a schematic illustration of a portion of matrix 402 and illustratively showing the orientation of the reinforcement particles 400 relative to the loading direction of the material and/or a scaffold strut, which is, for example, at an angle ⁇ .
  • the reinforcement particles 104 may have a maximum dimension from about 20 nm to about 2 mm, and for example, between 20 nm to about 100 ⁇ m. While both nano- and micro-scale calcium phosphate particles improve the mechanical properties of the example synthetic composite material 100 described herein, nano-scale calcium phosphate particles are particularly effective for enhancing bioresorbability and cell attachment, and micro-scale particles are particularly effective for obtaining a uniform dispersion within the matrix 102 .
  • Suitable calcium phosphates may include, without limitation, calcium HA, HA whiskers, HA, carbonated calcium HA, beta-tricalcium phosphate (beta-TCP), alpha-tricalcium phosphate (alpha-TCP), amorphous calcium phosphate (ACP), octacalcium phosphate (OCP), tetracalcium phosphate, biphasic calcium phosphate (BCP), anhydrous dicalcium phosphate (DCPA), dicalcium phosphate dihydrate (DCPD), anhydrous monocalcium phosphate (MCPA), monocalcium phosphate monohydrate (MCPM), and combinations thereof.
  • DCPA dicalcium phosphate
  • DCPD dicalcium phosphate dihydrate
  • MCPA monocalcium phosphate monohydrate
  • MCPM monocalcium phosphate monohydrate
  • a synthetic composite material 100 not only bears physiological levels of load, but also promotes oseteointegration—the direct structural and functional connection between the living bone and the surface of the load-bearing implant.
  • the bioactive calcium phosphate particles 104 e.g., HA whiskers
  • exposed on the surface of the example porous matrix 102 promote a stable bone-implant interface. Osteointegration also requires the vascularization and growth of bone into an implant via interconnected and/or continuous porosity.
  • the size, volume fraction, shape, and directionality of the void spaces and/or pores 106 may be tailored to optimize osteoconduction and implant mechanical properties.
  • the pores 106 may be any size or shape, while maintaining a continuous network to promote a fusion through the formation of new bone tissue in the void spaces and/or pores 106 .
  • the pores 106 may be present throughout the matrix 102 as illustrated in FIG. 1A .
  • the pores 106 may be functionally graded in any material or implant direction, for example, radially, as shown in FIGS. 6 and 7 , from a highly porous region to a relatively dense region or may include a void space.
  • the change in porosity from one region to another may be very distinct, for example as shown in FIGS.
  • the graded change may be uniform or variant.
  • the central void may be any shape or size, and may receive (e.g., be filled) a material, a structure, or the composite material 100 (i.e., the composite material graded from the porous outer surface to a dense center), thereby forming a porous outer perimeter and a dense central region. Examples are further described in connection with FIGS. 6 and 7 below.
  • the porosity and/or pore sizes 106 may be selectively formed by the inclusion of, for example, a porogen material during synthesis of the composite material 100 .
  • Pores spaces may range from about 100 ⁇ m to about 500 ⁇ m, and, for example, from about 250 ⁇ m to about 500 ⁇ m.
  • the example composite biomaterial 100 may additionally contain some fraction of microporosity within scaffold struts that is less than about 10 ⁇ m in size.
  • the total amount of porosity within porous regions may range from about 1% to about 90% by volume, and, for example, between about 70% and 90% by volume.
  • the porosity may also be tailored via other processes such as, for example, microsphere sintering, fiber weaving, solvent casting, electrospinning, freeze drying (lyophilization), thermally induced phase separation, gas foaming, and rapid prototyping processes such as, for example, solid freeform fabrication, robotic deposition (aka, robocasting), selective laser sintering, fused deposition modeling, three-dimensional printing, laminated object manufacturing, stereolithography, etc., or any other suitable process(es) or combination(s) thereof.
  • processes such as, for example, microsphere sintering, fiber weaving, solvent casting, electrospinning, freeze drying (lyophilization), thermally induced phase separation, gas foaming, and rapid prototyping processes such as, for example, solid freeform fabrication, robotic deposition (aka, robocasting), selective laser sintering, fused deposition modeling, three-dimensional printing, laminated object manufacturing, stereolithography, etc., or any other suitable process(es) or combination(s) thereof.
  • the example composite material 100 may optionally include additives, if desired.
  • the composite material 100 may include one or more surface-active agents to enhance interfacial bonding between the reinforcement particles 104 and the polymer matrix 102 .
  • the void spaces and/or pores 106 may accommodate and deliver one or more growth factors such as, for example, BMP, to enhance osteoinductivity and/or bone regeneration.
  • the void spaces and/or pores 106 may also accommodate and deliver one or more transcription factors, matrix metalloproteinases, peptides, proteins, bone cells, progenitor cells, blood plasma, bone marrow aspirate, or combinations thereof, to improve or speed bone regeneration, or resorption and replacement of the biomaterial.
  • the void spaces and/or pores 106 may further accommodate a carrier material that may be incorporated into the void spaces and/or pores 106 .
  • the carrier material may include, for example, a collagen sponge, membrane, or a hydrogel material to deliver the growth factor material such as, for example, the BMP.
  • FIG. 5A is an illustration showing a known interbody spinal fusion cage 500 .
  • the example spinal fusion cage 500 is implanted in the inter-vertebral space 502 between two adjacent vertebrae 506 and 508 .
  • a disc 510 due to degeneration, herniation, etc., is typically removed and replaced by the spinal fusion cage 500 .
  • the spinal fusion cage 500 is used to support or restore vertebral height, and, thus, stabilize or retain adjacent vertebrae 506 and 508 in a desired position. Additionally, the spinal fusion cage 500 is to promote fusion between the vertebrae 506 and 508 .
  • FIG. 5B is an enlarged illustration of the known spinal fusion cage 500 of FIG. 5A .
  • a typical spinal fusion cage 500 includes a body 510 having a dense outer region 512 and a void 514 at its center.
  • the dense outer surface 512 may be made of PEEK, titanium, or other material that can be used to support the vertebrae 506 and 508 .
  • the spinal fusion cage 500 made of a PEEK, titanium, etc. cannot attach to the bone.
  • the center void 514 is typically provided with a packing material (not shown) such as, a natural bone graft, a collagen sponge that retains bone growth factors, or the spinal fusion cage 500 is coated with the bone growth factors or other agents that promote osteoinduction.
  • the example porous scaffold 101 having the composite material 100 described herein, and with respect to FIG. 1A can be implemented with the spinal fusion cage 500 of FIGS. 5A and 5B to replace the packing materials, such as natural bone graft.
  • the porous scaffold 101 promotes bone ingrowth and the pores 106 may accommodate or deliver for example, a BMP, to further improve rate of growth (fusion rate).
  • the calcium phosphate e.g., HA whisker
  • FIG. 6 illustrates another example scaffold or matrix 600 implemented with the example composite material 100 described herein.
  • the example scaffold 600 may be implemented as an interbody spinal fusion cage.
  • the scaffold 600 includes a body 602 having a porous polymer matrix 604 integrally formed or embedded with anisometric calcium phosphate particles 606 .
  • the matrix 604 of the example scaffold 600 includes a radiolucent polymer (e.g., PEEK) integrally formed or embedded with anisometric calcium phosphate reinforcements 606 such as, for example, HA whiskers.
  • the radiolucent polymer provides improved radiographic analysis of fusion following implantation.
  • the example scaffold 600 may also include a BMP such as, for example, rhBMP- 2 .
  • the example scaffold 600 is a biocompatible, microporous polymer scaffold or matrix supplemented with anisometric calcium phosphate reinforcements and BMP.
  • the example scaffold 600 may formed so that the pores are functionally graded in any material or implant direction such as, for example, radially, as shown in FIG. 6 , from a highly porous center or central region 608 to relatively dense outer region or surface 610 .
  • the change in porosity from one region to another may be distinct or gradual from the central region 608 to the outer region 610 . Further, the graded change may be uniform or variant.
  • the dense outer region 610 provides structural integrity along with the advantages of the composite material 100 described herein.
  • the porous structure 604 has pore sizes that range between about 100 ⁇ m and about 500 ⁇ m, and preferably, between about 250 ⁇ m and about 500 ⁇ m, and a porosity that ranges between about 1% to about 90%.
  • FIG. 7 illustrates another example scaffold 700 .
  • the porous scaffold 700 includes a porous matrix 702 having the composite material 100 described herein.
  • the porous scaffold 700 includes a center or central void 704 that may be any shape or size.
  • the central void 704 may receive a material 706 , a stem, or any other substance or structure, illustratively depicted by dashed lines.
  • the central void 704 may receive a stem 706 (e.g., an implant) such as, for example, a titanium stem, a dense composite stem (e.g., a PEEK composite stem), or any other suitable material or structure.
  • a stem 706 e.g., an implant
  • a dense composite stem e.g., a PEEK composite stem
  • the scaffold 700 is formed so that the pores are functionally graded in any material or implant direction, for example, radially as shown in FIG. 7 , from a high porous outer region or surface 702 to a relatively dense center or central region 708 .
  • the change in porosity from one region to another may be distinct or gradual from the central region 708 to the highly porous outer region 702 .
  • the graded change may be uniform or variant.
  • the example scaffold 700 forms a porous perimeter having a dense core, where the material is continuous from the porous perimeter to the dense core.
  • the dense central region 708 provides structural integrity along with the advantages of the composite material 100 described herein.
  • the porous matrix 702 and the dense central region 708 may have pore sizes that range between about 100 ⁇ m and about 500 ⁇ m, and preferably, between about 250 ⁇ m and about 500 ⁇ m, and a porosity that ranges between about 1% to about 90%.
  • the spinal fusion cage 700 may include a microporosity having pore sizes less than about 10 ⁇ m.
  • the composite material 100 and/or the scaffolds 101 , 600 , 700 may also include a roughened surface such as, for example, serrated teeth, that come into direct contact with the adjacent peri-implant tissue to prevent movement relative to the peri-implant tissue after implantation.
  • the scaffolds 101 , 600 , 700 may include holes, notches, pins, radiographic markers, or other features that may be gripped or otherwise used for positioning of the scaffolds 101 , 600 , 700 by minimally invasive surgical tools and procedures.
  • the example composite material 100 and/or the scaffolds 101 , 600 , 700 may be manufactured by methods common to reinforced thermoplastic and thermosetting polymers, including but not limited to injection molding, reaction injection molding, compression molding, transfer molding, extrusion, blow molding, pultrusion, casting/potting, solvent casting, microsphere sintering, fiber weaving, solvent casting, electrospinning, freeze drying (lyophilization), thermally induced phase separation, gas foaming, and rapid prototyping processes such as solid freeform fabrication, robotic deposition (aka, robocasting), selective laser sintering, fused deposition modeling, three-dimensional printing, laminated object manufacturing, stereolithography, etc., or any other suitable process(es) or combination(s) thereof.
  • methods common to reinforced thermoplastic and thermosetting polymers including but not limited to injection molding, reaction injection molding, compression molding, transfer molding, extrusion, blow molding, pultrusion, casting/potting, solvent casting, microsphere sintering, fiber weaving, solvent casting, electrospinning, freeze drying (lyophilization), thermally
  • FIG. 8 is a flowchart of an example method 800 that may be used to synthesize the example composite material 100 and/or scaffolds 101 , 600 , 700 described herein. While an example manner of synthesizing the example composite material 100 and/or scaffolds 101 , 600 , 700 has been illustrated in FIG. 8 , one or more of the steps and/or processes illustrated in FIG. 8 may be combined, divided, re-arranged, omitted, eliminated and/or implemented in any other way. Further still, the example method of FIG. 8 may include one or more processes and/or steps in addition to, or instead of, those illustrated in FIG. 8 , and/or may include more than one of any or all of the illustrated processes and/or steps. Further, although the example method is described with reference to the flow chart illustrated in FIG. 8 , persons of ordinary skill in the art will readily appreciate that many other methods of synthesizing the example composite material 100 and/or scaffolds 101 , 600 , 700 may alternatively be used.
  • the composite material 100 and/or the scaffolds 101 , 600 , 700 are processed using a powder processing approach in conjunction with compression molding and particle leaching techniques and is particularly suited for achieving a high concentration (e.g., >40 vol %) of well-dispersed (and aligned, if desired) anisometric calcium phosphate reinforcements (e.g., HA whiskers) in a thermoplastic matrix (e.g., PEEK) with minimal degradation of the calcium phosphate size/shape during processing.
  • a high concentration e.g., >40 vol %
  • anisometric calcium phosphate reinforcements e.g., HA whiskers
  • a thermoplastic matrix e.g., PEEK
  • the calcium phosphate reinforcement volume fraction, aspect ratio, size and orientation; the polymer; and the size, volume fraction, shape and directionality of the void space and/or porosity may be tailored to vary the mechanical properties of the composite material 100 and/or scaffolds 101 , 600 , 700 .
  • a polymer such as, for example, PEEK, and anisometric calcium phosphate particles, such as HA whiskers, are provide in powder form (block 802 ).
  • the PEEK polymer powder may have, for example, a mean particle size of about 26 ⁇ m.
  • the HA whiskers may be synthesized (block 801 ) using, for example, the chelate decomposition method.
  • the PEEK powder and the synthesized HA whiskers are co-dispersed in a fluid (block 804 ) such as, for example ethanol, and mixed (block 804 ) using, for example, ultrasonication under constant stirring—forming a viscous suspension.
  • a fluid such as, for example ethanol
  • the porosity of the mixture is selectively varied and/or tailored (block 806 ).
  • the porosity may be formed and tailored by the addition of a suitable porogen material such as, for example, NaCl, wax, polysaccharides (sugars), cellulose, etc.
  • the extent of the porosity can be controlled by varying the amount of porogen used (block 805 ), while the pore size could be tailored by sieving the porogen (block 807 ) to a desired size prior to mixing the porogen with the polymer mixture.
  • the porosity and/or the pore size of the polymer matrix may be selectively varied using any other suitable methods and/or process(es) such as, for example, microsphere sintering, fiber weaving, solvent casting, electrospinning, freeze drying (lyophilization), thermally induced phase separation, gas foaming, or rapid prototyping processes such as, for example, solid freeform fabrication, robotic deposition (aka, robocasting), selective laser sintering, fused deposition modeling, three-dimensional printing, laminated object manufacturing, stereolithography, etc., or any other suitable process(es) or combination(s) thereof.
  • suitable methods and/or process(es) such as, for example, microsphere sintering, fiber weaving, solvent casting, electrospinning, freeze drying (lyophilization), thermally induced phase separation, gas foaming, or rapid prototyping processes such as, for example, solid freeform fabrication, robotic deposition (aka, robocasting), selective laser sintering, fused deposition modeling, three-dimensional printing, laminated object manufacturing
  • the viscous suspension is wet-consolidated (block 808 ) by, for example, vacuum filtration and drying to remove any residual fluid (i.e., ethanol).
  • the composite mixture is densified (block 810 ) by, for example, uniaxial compression, to form a composite preform.
  • the preform is compression molded (block 812 ) and/or sintered at elevated temperatures (e.g., approximately 20° C. to 400° C.) sufficient to fuse the polymer particles with minimal damage to the calcium phosphate reinforcements.
  • elevated temperatures e.g., approximately 20° C. to 400° C.
  • the process or composite material may be heated to a desired processing temperature and the implant may be shaped or formed (block 814 ). Densifying and molding the composite material includes aligning the calcium phosphate reinforcement particles (e.g., HA whiskers) morphologically and/or crystallographically within the scaffold struts.
  • the scaffold may have any shape and/or size (e.g., any polygonal shape) and can be formed by methods common to reinforced thermoplastic and thermosetting polymers, including but not limited to injection molding, reaction injection molding, compression molding, transfer molding, extrusion, blow molding, pultrusion, casting/potting, solvent casting, and rapid prototyping processes such as, for example, solid freeform fabrication, robotic deposition (aka, robocasting), selective laser sintering, fused deposition modeling, three-dimensional printing, laminated object manufacturing, stereolithography, etc., or any other suitable process(es).
  • the composite material 100 and/or the scaffolds 101 , 600 , 700 are formed by the mold walls and/or machining after molding.
  • the composite material undergoes a leaching process (block 816 ) to remove, for example, the porogen used during synthesis of the composite material.
  • the leaching may occur, for example, via a dissolution method, heating method, and/or any other suitable methods and/or process(es). More specifically, dissolution may include immersing the scaffold in a fluid, such as, for example, deionized water.
  • viscous flow of the polymer/reinforcement mixture during molding can be designed to tailor the preferred orientation of the anisometric reinforcements in the implant.
  • surface-active agents may be added during the mixing process and/or to the surface of the composite material to enhance interfacial bonding between reinforcement particles and the matrix.
  • HA whiskers were synthesized using the chelate decomposition method. The as-synthesized HA whiskers were measured by optical microscopy to have a mean length of 21.6 ⁇ m, width of ⁇ m and aspect ratio of 7.6.
  • composite scaffolds with 75, 82.5 and 90% porosity were processed with 0-40 vol % HA whisker reinforcement.
  • Appropriate amounts of polymer powder and HA whiskers were co-dispersed in ethanol via a sonic dismembrator and mechanical stirring at 1200 rpm.
  • the appropriate amount of the NaCl i.e., porogen
  • the total scaffold volume consisted of the material volume plus the pore volume.
  • the reinforcement level was calculated based the desired material volume, while the porosity level was calculated based on the total scaffold volume.
  • the viscous suspension was wet-consolidated using vacuum filtration.
  • the powder mixture was dried overnight in a forced convection oven at 90° C. and densified at 125 MPa in a cylindrical pellet die using a hydraulic platen press.
  • the die and densified powder mixture was heated in a vacuum oven to the desired processing temperature and transferred to a hydraulic platen press for compression molding. Scaffolds with 82.5 and 90% porosity were molded at 350° C., while scaffolds with 75% porosity were molded at 350, 365 and 375° C.
  • a pressure of 250 MPa was applied to the die as the polymer solidified.
  • the sintered composite pellet was ejected from the die and placed approximately 300 mL deionized water for at least 72 h to dissolve the NaCl crystals. The deionized water was changed daily.
  • the as-molded composite scaffolds had a diameter of 1 cm and were machined to a height of 1 cm.
  • the table below provides mechanical properties of the example PEKK scaffold reinforced with HA whiskers that was processed using a compression molding/particle leaching method such as, for example, the method 800 of FIG. 8 as implemented in the description above.
  • the mechanical properties of HA whisker reinforced PEKK were evaluated in uniaxial compression.
  • Tensile properties of the HA whisker reinforced PEKK scaffolds were evaluated prior to scaffold fabrication.
  • Scaffolds with 0 vol % HA whisker reinforcement and 75% and 90% porosity exhibited yield strengths of 1.25 MPa and 0.15 MPa, respectively.
  • Scaffolds with 40 vol % HA whisker reinforcement and 75%, 82% and 90% porosity exhibited yield strengths of 0.52 MPa, 0.13 MPa and 0.04 MPa, respectively.
  • the HA content also affected the modulus and failure strain of the scaffolds.
  • a scaffold having 75% porosity and 20 vol % reinforcement HA whisker exhibited modulus of 106.3 MPa, compared to a modulus of 69.5 MPa for scaffolds with 0 vol % HA whisker reinforcement.
  • the example methods and apparatus described herein offer synthetic porous composite material that may be used for synthetic bone substitutes for implant fixation, fraction fixation, synthetic bone graft substitutes, interbody spinal fusion, tissue engineering scaffolds, or other applications.
  • Many aspects of the of the porous composite material may be tailored to provide specific mechanical, biological, and surgical functions, such as, the polymer composition and molecular orientation, porosity and pore size of the porous matrix, or the HA reinforcement content, morphology, preferred orientation, and size.

Abstract

A composite material for use, for example, as an orthopedic implant, that includes a porous reinforced composite scaffold that includes a polymer, reinforcement particles distributed throughout the polymer, and a substantially continuously interconnected plurality of pores that are distributed throughout the polymer, each of the pores in the plurality of pores defined by voids interconnected by struts, each pore void having a size within a range from about 10 to 500 μm. The porous reinforced composite scaffold has a scaffold volume that includes a material volume defined by the polymer and the reinforcement particles, and a pore volume defined by the plurality of pores. The reinforcement particles are both embedded within the polymer and exposed on the struts within the pore voids. The polymer may be a polyaryletherketone polymer and the reinforcement particles may be anisometric calcium phosphate particles.

Description

  • This application is a continuation of and claims priority to U.S. patent application Ser. No. 14/078,614, filed on Nov. 13, 2013, entitled “Porous Composite Biomaterials and Related Methods,” now patented, which is a continuation of U.S. patent application Ser. No. 12/039,666, filed on Feb. 28, 2008, entitled “Porous Composite Biomaterials and Related Methods,” which claims the benefit of U.S. Provisional Patent Application Ser. No. 60/904,098, filed on Feb. 28, 2007, entitled “Reinforced Porous Polymer Scaffolds,” and U.S. Provisional Patent Application Ser. No. 60/939,256, filed on May 21, 2007, entitled “Interbody Spinal Fusion Cages Containing Anisometric Calcium Phosphate Reinforcements and Related Methods,” each of which is incorporated herein by reference in its entirety.
  • FIELD OF THE DISCLOSURE
  • The present disclosure relates generally to composite biomaterials and more particularly to porous composite biomaterials and related methods.
  • BACKGROUND
  • Natural bone grafts such as autogenous bone grafts (autografts) are commonly used in procedures for repairing or replacing bone defects because they provide good structural support and osteoinductivity. Natural bone grafts involve removing or harvesting tissue from another part of a host's body (e.g., typically from the iliac crest, hip, ribs, etc.) and implanting the harvested tissue in the defect site. Not only do these grafts require an added surgical procedure needed to harvest the bone tissue, these grafts have limitations, including for example, transplant site morbidity. One alternative to autografts is allografts, which involve removing and transplanting tissue from another human (e.g., from bone banks that harvest bone tissue from cadavers) to the defect site. However, allografts are known to induce infection and immunotoxicity, suffer from limited supply and variability, and have a lessened effectiveness because the cells and proteins that promote bone growth are lost during the harvesting process (e.g., during cleansing and disinfecting process). Demineralized bone matrix (DBM) is typically used to induce bone growth at defect sites, but DBM lacks the mechanical properties (e.g., stiffness, strength, toughness, etc.) necessary to be considered a viable option for load-bearing applications.
  • Synthetic bone substitute materials have been researched in the treatment of diseased bone (e.g., osteoporosis), injured bone (e.g., fractures), or other bone defects in lieu of natural bone grafts. Synthetic bone substitutes are viable alternatives to the more traditional methods described above. However, synthetic substitute materials used to repair diseased bones and joints should function or perform biologically and mechanically (i.e., as the structural support role of the bone itself) by, for example, mimicking the density and overall physical structure of natural bone to provide a framework for ingrowth of new tissue. One type or application of a synthetic bone substitute is a scaffold, which provides support for bone-producing cells. Scaffolds may be biodegradable, which degrade in vivo, or they may be non-biodegradable to provide permanent implant fixation (e.g., spinal fusion cages). In addition, scaffolds are typically biocompatible, and some may be bioactive, bioresorbable, osteoconductive, and/or osteoinductive. The shapability, deliverability, cost, and ability to match the mechanical properties of the surrounding host tissue are other factors that vary among different types of scaffolds and other bone substitutes.
  • Problems may arise when there is a mechanical mismatch between the bone substitute and the surrounding tissue. For example, metallic implants and dense ceramics have mechanical properties that are typically an order of magnitude greater than the bone tissue. As a result, a stiff metal bone substitute implant acts to “shield” the adjacent bone tissue from mechanical stresses, resulting in a weakened bone at the bone-implant interface. Furthermore, efforts to utilize porous ceramics or polymer bone cement in place of stiffer materials have been limited. For example, ceramics possess low fracture toughness, thereby making the orthopedic implant brittle (i.e., susceptible to fracture). Polymers are limited by higher compliance and lower strength, thereby limiting their ability to support physiological load levels. Additionally, conventional orthopedic implant biomaterials are not osteoconductive and bioactive, resulting in a lack of bonding between the implant and the peri-implant tissue.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1A is a perspective view of an example porous composite material described herein.
  • FIG. 1B is a cross-sectional view of a portion of the example porous composite material of FIG. 1A.
  • FIG. 2A-2C are scanning electron micrographs of a portion of the example porous composite material shown in increasing magnification.
  • FIGS. 3 is graphical representation of the elastic modulus of example apatite reinforced polymer composites versus the reinforcement volume fraction.
  • FIG. 4 shows scanning electron micrograph of a portion of the surface of an example composite material reinforced with calcium phosphate whiskers embedded within and exposed on the surface, and schematically showing the orientation of the whiskers relative to the loading direction of the material or scaffold strut.
  • FIG. 5A is a schematic illustration of a known spinal fusion cage inserted between spinal vertebrae.
  • FIG. 5B illustrates the example known spinal fusion cage of FIG. 5A.
  • FIG. 6 illustrates another example scaffold described herein.
  • FIG. 7 illustrates yet another example scaffold described herein.
  • FIG. 8 is a flow diagram illustrating an example process of creating an example composite material apparatus described herein.
  • DETAILED DESCRIPTION
  • In general, the example methods, apparatus, and materials described herein provide a biocompatible, bioactive synthetic porous composite for use as synthetic bone substitute materials. The synthetic composite may provide a synthetic porous scaffold for use an orthopedic implant and/or be injectable via percutaneous or surgical injection to cure in vivo. Because the example composite material is used to form a scaffold or matrix that is used in an implantable device, the descriptions of one or more of these structures may also describe one or more of the other structures. The synthetic porous composites are tailored to mimic biological and mechanical properties of bone tissue for implant fixation, synthetic bone graft substitutes, tissue engineering scaffolds, interbody spinal fusion, or other orthopedic applications. An example porous composite material described herein reduces subsidence and/or bone resorption resulting from mechanical mismatch problems between a synthetic scaffold of an implant device and the peri-implant tissue. Additionally, porosity and/or the pore sizes of the example synthetic composite are tailorable to specific applications to effectively promote the vascularization and growth of bone in the pores and/or void spaces of the example scaffolds, thereby improving bonding between the scaffolds and peri-implant tissue.
  • The example composite material or scaffolds are synthesized or made through a process that enables reinforcement particles to be integrally formed with or embedded within polymer matrices. In this manner, the polymer matrices embedded with the reinforcement material provide improved material properties (e.g., stiffness, fatigue strength, and toughness). The reinforcement particles are also exposed on a surface of the matrices, which promotes bioactivity and/or bioresorption. Additionally, the process provides flexibility to tailor the level of reinforcement particles and porosity for a desired application. For example, a porogen material may be used to vary the porosity, while the pore size is tailored by, for example, sieving the porogen to a desired size.
  • By varying the volume of the reinforcement particles and the porosity of the example scaffold, the mechanical properties (e.g., stiffness, strength, toughness, etc.) of the example scaffold of the implant device may be tailored to match those of the adjacent peri-implant bone tissue to reduce mechanical mismatch problems. Reducing mechanical mismatch provides a decreased risk of subsidence, stress shielding, bone resorption, and/or subsequent failure of adjacent peri-implant bone tissue. Additionally, the example scaffold of the implant device may include a significantly high porosity to promote bone ingrowth, while exhibiting significantly higher effective mechanical properties such as, for example, the mechanical properties of trabecular bone.
  • In particular, the example composite material includes a continuous porous biocompatible matrix having a thermoplastic polymer matrix reinforced with anisometric calcium phosphate particles. More specifically, in one example, a composite material includes a polyetheretherketone (PEEK) or a polyetherketoneketone (PEKK) matrix reinforced with various volume fractions of hydroxyapatite (HA) whiskers (e.g., 20 or 40 volume percent), wherein the matrix is approximately between 70% and 90% porous. In another example, the porous matrix includes a biocompatible, microporous polymer cage reinforced with anisometric calcium phosphate particles and bone morphogenic protein (BMP) such as, for example, rhBMP-2, which can be dispersed or accommodated by the void spaces and/or pores of the example porous scaffold and/or exposed on the surface of the example porous scaffold. Additionally, the BMP binds to the calcium phosphate further localizing the BMP to the surface of the scaffold or matrix.
  • The example composite materials described herein may be used for applications such as, for example, synthetic bone graft substitutes, bone ingrowth surfaces applied to existing implants, tissue engineering scaffolds, interbody spinal fusion cages, etc. In each of the applications, carrier materials (e.g., collagen, hydrogels, etc.) containing growth factors, such as BMP, may be incorporated into the pore space of the scaffold of the implant device to further enhance osteoinduction and/or osteoconduction to promote osteointegration.
  • Human bone tissues exhibit substantial variation in mechanical properties depending on the tissue density and microstructure. The properties are highly dependent on anatomic location and apparent density of the measured specimen. For example, a femur includes a cortical bone that has a relative porosity on the order of about 5-15%, and a trabecular bone that has a porosity on the order of about 75-95%. Due to the highly significant porosity differences, the trabecular bone exhibits significantly lower effective mechanical properties compared to the cortical bone. Therefore, depending on the application, synthetic composite materials for use as scaffolds and/or spinal fusion cages or other implant devices should possess the mechanical properties exhibited by the cortical bone or the trabecular bone, but must also have effective porosity to promote bone growth.
  • To avoid the mechanical mismatch problems, such as stress shielding, the example scaffold of the implant device described herein may be tailored to substantially match or mimic the mechanical properties (e.g., stiffness, strength, toughness, etc.) of the adjacent and/or substituted bone tissue. Several factors may be varied during the synthesis of the composite material and scaffold of the implant device to tailor the mechanical properties including the calcium phosphate reinforcement volume fraction, aspect ratio, size and orientation; the polymer; and the size, volume fraction, shape and directionality of the void space and/or porosity. Tailoring the mechanical properties of the scaffold reduces the likelihood of mechanical mismatch leading to a decreased risk of subsidence, stress shielding, bone resorption and/or subsequent failure of adjacent vertebrae.
  • FIG. 1A illustrates the example synthetic porous composite material 100 described herein. FIG. 1B is a cross-sectional view of a portion of the example porous composite material 100 of FIG. 1A. The example synthetic composite material 100 provides a synthetic porous scaffold 101 for use or in as an orthopedic implant.
  • The example synthetic porous composite material 100 includes a porous thermoplastic polymer (e.g., a PEEK polymer) matrix 102 having anisometric calcium phosphate reinforcement particles 104 integrally formed or embedded with the matrix 102 and/or exposed on a surface of the matrix. In this manner, the polymer matrix 102 embedded with the reinforcement particles 104 provides high material strength, and the reinforcement particles 104 exposed on the surface of the matrix 102 promote bioactivity and/or bioresorption. The porous polymer matrix 102 includes a substantially continuous porosity and a plurality of pores 106 to enable bone ingrowth into the porous matrix 102. In addition, the matrix 102 is substantially continuously interconnected via a plurality of struts 108.
  • Furthermore, at least one of the plurality of struts 108 may be a load-bearing strut.
  • FIGS. 2A-2C are scanning electron micrographs showing increasing magnification of a portion of an example scaffold 200 with struts 202. The example scaffold 200 is a PEEK scaffold reinforced with 40% by volume HA whiskers 204. FIG. 2A illustrates the architecture or matrix 206 of the scaffold 200 and FIG. 2B illustrates an enlarged portion of the struts 202. In the illustrated example, the HA whiskers 204 are integrally formed and/or embedded within the matrix 206 of the scaffold 200 for reinforcement. The HA whiskers 204 are also exposed on a surface 208 of the matrix of the scaffold 200 for bioactivity and/or bioresorption, as noted above. As shown in FIG. 2C, the HA whiskers 204 are aligned in a sheet texture and are exposed on the surface 208 of the struts 202.
  • The thermoplastic polymer of the example scaffolds described herein may be a biodegradable polymer for synthetic bone graft substitute applications, or nonbiodegradable for implant fixation applications. The thermoplastic polymer includes a continuous matrix of a composite material and is biocompatible and/or bioresorbable as described above.
  • Additionally, or alternatively, the polymer may be a radiolucent polymer, bioresorbable (i.e., a material capable of being resorbed by a patient under normal physiological conditions) and/or non-bioresorbable, as desired. Further, the thermoplastic polymer matrix may include a polymer suitable for injection via percutaneous or surgical injection so that the composite material 100 cures in vivo.
  • Suitable non-resorbable polymers include, without limitation, polyaryletherketone (PAEK), polyetheretherketone (PEEK), polyetherketonekteone (PEKK), polyetherketone (PEK), polyethylene, high density polyethylene (HDPE), ultra-high molecular weight polyethylene (UHMWPE), low density polyethylene (LDPE), polyethylene oxide (PEO), polyurethane, polypropylene, polypropylene oxide (PPO), polysulfone, polypropylene, copolymers thereof, and blends thereof. Suitable bioresorbable polymers include, without limitation, poly(DL-lactide) (PDLA), poly(L-lactide) (PLLA), poly(glycolide) (PGA), poly(□-caprolactone) (PCL), poly(dioxanone) (PDO), poly(glyconate), poly(hydroxybutyrate) (PHB), poly(hydroxyvalerate (PHV), poly(orthoesters), poly(carboxylates), poly(propylene fumarate), poly(phosphates), poly(carbonates), poly(anhydrides), poly(iminocarbonates), poly(phosphazenes), copolymers thereof, and blends thereof. Suitable polymers that are injectable via percutaneous or surgical injection that cure in vivo include, without limitation, polymethylmethacrylate (PMMA), and other polyacrylics from monomers such as bisphenol a hydroxypropylmethacrylate (bis-GMA) and/or tri(ethylene glycol) dimethacrylate (TEG-DMA).
  • Although synthetic substitute composite materials made of polymers satisfy the functional criteria of an implantable device because they are, for example, formable and inexpensive, polymers alone lack biological efficacy to promote bone growth and/or may lack requisite mechanical properties to support load levels. To increase the mechanical properties of the polymers, the polymers are reinforced with calcium phosphates. The aspect ratio, size, volume fraction and degree of preferred orientation of the calcium phosphate particles 104 (e.g., HA whisker particles) may be tailored for the desired material properties and implant performance. For example, consider the information presented in FIG. 3, which is a graphical illustration of the elastic modulus of HA whisker and powder reinforced polymer composite materials versus the volume fraction percentage of the apatite calcium phosphates that is mixed with the polymer matrix. The shaded areas of FIG. 3 show approximate regions for the given mechanical property of the human cortical bone tissue. As depicted in the graph, the elastic modulus of the composite materials increases with increasing HA content. In addition, increasing the level of HA reinforcement in polymer composites increases cellular activity during osteointegration.
  • The calcium phosphate reinforcement particles 104 may be in the form of single crystals or dense polycrystals but are at least in some portion anisometric. “Anisometric” refers to any particle morphology (shape) that is not equiaxed (e.g., spherical), such as whiskers, plates, fibers, etc. Anisometric particles are usually characterized by an aspect ratio. For example, HA single crystals are characterized by the ratio of dimensions in the c- and a-axes of the hexagonal crystal structure. Thus, the anisometric particles in the present disclosure have an aspect ratio greater than 1. In one example, the mean aspect ratio of the reinforcement particles is from about 1 to about 100. By further example, the reinforcement particles can be provided in an amount of from about 1% by volume of the composite biomaterial to about 60% by volume, and for example, from about 20% by volume of the composite to about 50% by volume.
  • Due to their morphology, the calcium phosphate reinforcements particles 104 may be oriented in bulk or near the surface of the polymer matrix 102 to provide directional properties, if desired. For example, if the reinforcement particles 104 are predominately aligned within the matrix 102 the morphological alignment of the particles 104 provides anisotropy for the overall composite 100, which can be tailored to be similar to the anisotropic mechanical properties of bone tissues. For example, FIG. 4 shows a micrograph of anisometric calcium phosphate reinforcement 400 on the surface of a dense composite polymer matrix 402. Also shown in FIG. 4 is a schematic illustration of a portion of matrix 402 and illustratively showing the orientation of the reinforcement particles 400 relative to the loading direction of the material and/or a scaffold strut, which is, for example, at an angle θ.
  • Furthermore, there are no limits on the size or amount of the calcium phosphate particles 104 in matrix 102, provided that the calcium phosphate particles 104 are dispersed within and/or exposed at the surface of the polymer matrix 102. For example, the reinforcement particles 104 may have a maximum dimension from about 20 nm to about 2 mm, and for example, between 20 nm to about 100 μm. While both nano- and micro-scale calcium phosphate particles improve the mechanical properties of the example synthetic composite material 100 described herein, nano-scale calcium phosphate particles are particularly effective for enhancing bioresorbability and cell attachment, and micro-scale particles are particularly effective for obtaining a uniform dispersion within the matrix 102.
  • Suitable calcium phosphates may include, without limitation, calcium HA, HA whiskers, HA, carbonated calcium HA, beta-tricalcium phosphate (beta-TCP), alpha-tricalcium phosphate (alpha-TCP), amorphous calcium phosphate (ACP), octacalcium phosphate (OCP), tetracalcium phosphate, biphasic calcium phosphate (BCP), anhydrous dicalcium phosphate (DCPA), dicalcium phosphate dihydrate (DCPD), anhydrous monocalcium phosphate (MCPA), monocalcium phosphate monohydrate (MCPM), and combinations thereof.
  • As described above, a synthetic composite material 100 not only bears physiological levels of load, but also promotes oseteointegration—the direct structural and functional connection between the living bone and the surface of the load-bearing implant. The bioactive calcium phosphate particles 104 (e.g., HA whiskers) exposed on the surface of the example porous matrix 102 promote a stable bone-implant interface. Osteointegration also requires the vascularization and growth of bone into an implant via interconnected and/or continuous porosity.
  • Thus, the size, volume fraction, shape, and directionality of the void spaces and/or pores 106 may be tailored to optimize osteoconduction and implant mechanical properties. The pores 106 may be any size or shape, while maintaining a continuous network to promote a fusion through the formation of new bone tissue in the void spaces and/or pores 106. For example, the pores 106 may be present throughout the matrix 102 as illustrated in FIG. 1A. Also, the pores 106 may be functionally graded in any material or implant direction, for example, radially, as shown in FIGS. 6 and 7, from a highly porous region to a relatively dense region or may include a void space. The change in porosity from one region to another may be very distinct, for example as shown in FIGS. 6 and 7, or gradual. Furthermore, the graded change may be uniform or variant. In addition, instead of a graded change there may be a combination of materials having two or more densities of pores. The central void may be any shape or size, and may receive (e.g., be filled) a material, a structure, or the composite material 100 (i.e., the composite material graded from the porous outer surface to a dense center), thereby forming a porous outer perimeter and a dense central region. Examples are further described in connection with FIGS. 6 and 7 below.
  • As discussed in greater detail below, the porosity and/or pore sizes 106 may be selectively formed by the inclusion of, for example, a porogen material during synthesis of the composite material 100. Pores spaces may range from about 100 μm to about 500 μm, and, for example, from about 250 μm to about 500 μm. The example composite biomaterial 100 may additionally contain some fraction of microporosity within scaffold struts that is less than about 10 μm in size. The total amount of porosity within porous regions may range from about 1% to about 90% by volume, and, for example, between about 70% and 90% by volume. However, the porosity may also be tailored via other processes such as, for example, microsphere sintering, fiber weaving, solvent casting, electrospinning, freeze drying (lyophilization), thermally induced phase separation, gas foaming, and rapid prototyping processes such as, for example, solid freeform fabrication, robotic deposition (aka, robocasting), selective laser sintering, fused deposition modeling, three-dimensional printing, laminated object manufacturing, stereolithography, etc., or any other suitable process(es) or combination(s) thereof.
  • Additionally, the example composite material 100 may optionally include additives, if desired. For example, the composite material 100 may include one or more surface-active agents to enhance interfacial bonding between the reinforcement particles 104 and the polymer matrix 102. The void spaces and/or pores 106 may accommodate and deliver one or more growth factors such as, for example, BMP, to enhance osteoinductivity and/or bone regeneration. Furthermore, the void spaces and/or pores 106 may also accommodate and deliver one or more transcription factors, matrix metalloproteinases, peptides, proteins, bone cells, progenitor cells, blood plasma, bone marrow aspirate, or combinations thereof, to improve or speed bone regeneration, or resorption and replacement of the biomaterial. In some examples, the void spaces and/or pores 106 may further accommodate a carrier material that may be incorporated into the void spaces and/or pores 106. The carrier material may include, for example, a collagen sponge, membrane, or a hydrogel material to deliver the growth factor material such as, for example, the BMP. The calcium phosphate reinforcements 104 exposed on the surface of the porous matrix 102, along with the porosity, improves the retention of the BMP within the matrix 102 and at the peri-implant interface.
  • FIG. 5A is an illustration showing a known interbody spinal fusion cage 500. The example spinal fusion cage 500 is implanted in the inter-vertebral space 502 between two adjacent vertebrae 506 and 508. A disc 510, due to degeneration, herniation, etc., is typically removed and replaced by the spinal fusion cage 500. The spinal fusion cage 500 is used to support or restore vertebral height, and, thus, stabilize or retain adjacent vertebrae 506 and 508 in a desired position. Additionally, the spinal fusion cage 500 is to promote fusion between the vertebrae 506 and 508.
  • FIG. 5B is an enlarged illustration of the known spinal fusion cage 500 of FIG. 5A. A typical spinal fusion cage 500 includes a body 510 having a dense outer region 512 and a void 514 at its center. The dense outer surface 512 may be made of PEEK, titanium, or other material that can be used to support the vertebrae 506 and 508. However, the spinal fusion cage 500 made of a PEEK, titanium, etc., cannot attach to the bone. Thus, to promote bone ingrowth, the center void 514 is typically provided with a packing material (not shown) such as, a natural bone graft, a collagen sponge that retains bone growth factors, or the spinal fusion cage 500 is coated with the bone growth factors or other agents that promote osteoinduction.
  • The example porous scaffold 101 having the composite material 100 described herein, and with respect to FIG. 1A, can be implemented with the spinal fusion cage 500 of FIGS. 5A and 5B to replace the packing materials, such as natural bone graft. As noted above, the porous scaffold 101 promotes bone ingrowth and the pores 106 may accommodate or deliver for example, a BMP, to further improve rate of growth (fusion rate). Furthermore, the calcium phosphate (e.g., HA whisker) binds to the body 510 and localizes the BMP within the central void 514, which further promotes osteointegration.
  • FIG. 6 illustrates another example scaffold or matrix 600 implemented with the example composite material 100 described herein. The example scaffold 600 may be implemented as an interbody spinal fusion cage. The scaffold 600 includes a body 602 having a porous polymer matrix 604 integrally formed or embedded with anisometric calcium phosphate particles 606. Furthermore, the matrix 604 of the example scaffold 600 includes a radiolucent polymer (e.g., PEEK) integrally formed or embedded with anisometric calcium phosphate reinforcements 606 such as, for example, HA whiskers. The radiolucent polymer provides improved radiographic analysis of fusion following implantation. The example scaffold 600 may also include a BMP such as, for example, rhBMP-2. In another example, the example scaffold 600 is a biocompatible, microporous polymer scaffold or matrix supplemented with anisometric calcium phosphate reinforcements and BMP.
  • Additionally, the example scaffold 600 may formed so that the pores are functionally graded in any material or implant direction such as, for example, radially, as shown in FIG. 6, from a highly porous center or central region 608 to relatively dense outer region or surface 610. The change in porosity from one region to another may be distinct or gradual from the central region 608 to the outer region 610. Further, the graded change may be uniform or variant. The dense outer region 610 provides structural integrity along with the advantages of the composite material 100 described herein. In the illustrated example, the porous structure 604 has pore sizes that range between about 100 μm and about 500 μm, and preferably, between about 250 μm and about 500 μm, and a porosity that ranges between about 1% to about 90%. Furthermore, the spinal fusion cage material 600 may include microporosity having pore sizes less than about 10 μm. FIG. 7 illustrates another example scaffold 700. The porous scaffold 700 includes a porous matrix 702 having the composite material 100 described herein. The porous scaffold 700 includes a center or central void 704 that may be any shape or size. Additionally, or alternatively, the central void 704 may receive a material 706, a stem, or any other substance or structure, illustratively depicted by dashed lines. For example, the central void 704 may receive a stem 706 (e.g., an implant) such as, for example, a titanium stem, a dense composite stem (e.g., a PEEK composite stem), or any other suitable material or structure.
  • Additionally, in other examples, the scaffold 700 is formed so that the pores are functionally graded in any material or implant direction, for example, radially as shown in FIG. 7, from a high porous outer region or surface 702 to a relatively dense center or central region 708. The change in porosity from one region to another may be distinct or gradual from the central region 708 to the highly porous outer region 702. Further, the graded change may be uniform or variant. In this manner, the example scaffold 700 forms a porous perimeter having a dense core, where the material is continuous from the porous perimeter to the dense core. The dense central region 708 provides structural integrity along with the advantages of the composite material 100 described herein. In the illustrated example, the porous matrix 702 and the dense central region 708 may have pore sizes that range between about 100 μm and about 500 μm, and preferably, between about 250 μm and about 500 μm, and a porosity that ranges between about 1% to about 90%. Furthermore, the spinal fusion cage 700 may include a microporosity having pore sizes less than about 10 μm.
  • In other examples, the composite material 100 and/or the scaffolds 101, 600, 700 may also include a roughened surface such as, for example, serrated teeth, that come into direct contact with the adjacent peri-implant tissue to prevent movement relative to the peri-implant tissue after implantation. Additionally, or alternatively, although not shown, the scaffolds 101, 600, 700 may include holes, notches, pins, radiographic markers, or other features that may be gripped or otherwise used for positioning of the scaffolds 101, 600, 700 by minimally invasive surgical tools and procedures.
  • The example composite material 100 and/or the scaffolds 101, 600, 700 may be manufactured by methods common to reinforced thermoplastic and thermosetting polymers, including but not limited to injection molding, reaction injection molding, compression molding, transfer molding, extrusion, blow molding, pultrusion, casting/potting, solvent casting, microsphere sintering, fiber weaving, solvent casting, electrospinning, freeze drying (lyophilization), thermally induced phase separation, gas foaming, and rapid prototyping processes such as solid freeform fabrication, robotic deposition (aka, robocasting), selective laser sintering, fused deposition modeling, three-dimensional printing, laminated object manufacturing, stereolithography, etc., or any other suitable process(es) or combination(s) thereof.
  • FIG. 8 is a flowchart of an example method 800 that may be used to synthesize the example composite material 100 and/or scaffolds 101, 600, 700 described herein. While an example manner of synthesizing the example composite material 100 and/or scaffolds 101, 600, 700 has been illustrated in FIG. 8, one or more of the steps and/or processes illustrated in FIG. 8 may be combined, divided, re-arranged, omitted, eliminated and/or implemented in any other way. Further still, the example method of FIG. 8 may include one or more processes and/or steps in addition to, or instead of, those illustrated in FIG. 8, and/or may include more than one of any or all of the illustrated processes and/or steps. Further, although the example method is described with reference to the flow chart illustrated in FIG. 8, persons of ordinary skill in the art will readily appreciate that many other methods of synthesizing the example composite material 100 and/or scaffolds 101, 600, 700 may alternatively be used.
  • The composite material 100 and/or the scaffolds 101, 600, 700 are processed using a powder processing approach in conjunction with compression molding and particle leaching techniques and is particularly suited for achieving a high concentration (e.g., >40 vol %) of well-dispersed (and aligned, if desired) anisometric calcium phosphate reinforcements (e.g., HA whiskers) in a thermoplastic matrix (e.g., PEEK) with minimal degradation of the calcium phosphate size/shape during processing. In this manner, the calcium phosphate reinforcement volume fraction, aspect ratio, size and orientation; the polymer; and the size, volume fraction, shape and directionality of the void space and/or porosity may be tailored to vary the mechanical properties of the composite material 100 and/or scaffolds 101, 600, 700.
  • A polymer such as, for example, PEEK, and anisometric calcium phosphate particles, such as HA whiskers, are provide in powder form (block 802). The PEEK polymer powder may have, for example, a mean particle size of about 26 μm. The HA whiskers may be synthesized (block 801) using, for example, the chelate decomposition method.
  • The PEEK powder and the synthesized HA whiskers are co-dispersed in a fluid (block 804) such as, for example ethanol, and mixed (block 804) using, for example, ultrasonication under constant stirring—forming a viscous suspension.
  • After the polymer powder and the HA whiskers are mixed, the porosity of the mixture is selectively varied and/or tailored (block 806). In one example, the porosity may be formed and tailored by the addition of a suitable porogen material such as, for example, NaCl, wax, polysaccharides (sugars), cellulose, etc. The extent of the porosity can be controlled by varying the amount of porogen used (block 805), while the pore size could be tailored by sieving the porogen (block 807) to a desired size prior to mixing the porogen with the polymer mixture. In another examples, the porosity and/or the pore size of the polymer matrix may be selectively varied using any other suitable methods and/or process(es) such as, for example, microsphere sintering, fiber weaving, solvent casting, electrospinning, freeze drying (lyophilization), thermally induced phase separation, gas foaming, or rapid prototyping processes such as, for example, solid freeform fabrication, robotic deposition (aka, robocasting), selective laser sintering, fused deposition modeling, three-dimensional printing, laminated object manufacturing, stereolithography, etc., or any other suitable process(es) or combination(s) thereof.
  • The viscous suspension is wet-consolidated (block 808) by, for example, vacuum filtration and drying to remove any residual fluid (i.e., ethanol). The composite mixture is densified (block 810) by, for example, uniaxial compression, to form a composite preform.
  • Following the initial densification, the preform is compression molded (block 812) and/or sintered at elevated temperatures (e.g., approximately 20° C. to 400° C.) sufficient to fuse the polymer particles with minimal damage to the calcium phosphate reinforcements. The process or composite material may be heated to a desired processing temperature and the implant may be shaped or formed (block 814). Densifying and molding the composite material includes aligning the calcium phosphate reinforcement particles (e.g., HA whiskers) morphologically and/or crystallographically within the scaffold struts.
  • The scaffold may have any shape and/or size (e.g., any polygonal shape) and can be formed by methods common to reinforced thermoplastic and thermosetting polymers, including but not limited to injection molding, reaction injection molding, compression molding, transfer molding, extrusion, blow molding, pultrusion, casting/potting, solvent casting, and rapid prototyping processes such as, for example, solid freeform fabrication, robotic deposition (aka, robocasting), selective laser sintering, fused deposition modeling, three-dimensional printing, laminated object manufacturing, stereolithography, etc., or any other suitable process(es). The composite material 100 and/or the scaffolds 101, 600, 700, are formed by the mold walls and/or machining after molding.
  • The composite material undergoes a leaching process (block 816) to remove, for example, the porogen used during synthesis of the composite material. The leaching may occur, for example, via a dissolution method, heating method, and/or any other suitable methods and/or process(es). More specifically, dissolution may include immersing the scaffold in a fluid, such as, for example, deionized water.
  • Furthermore, viscous flow of the polymer/reinforcement mixture during molding can be designed to tailor the preferred orientation of the anisometric reinforcements in the implant. Additionally, surface-active agents may be added during the mixing process and/or to the surface of the composite material to enhance interfacial bonding between reinforcement particles and the matrix.
  • The following example is provided to further illustrate the example apparatus and methods described herein and, of course, should not be construed as in any way limiting in scope. It is to be understood by one of ordinary skill in the art that the following examples are neither comprehensive nor exhaustive of the many types of methods and apparatus which may be prepared in accordance with the present disclosure.
  • In the example, commercially available PEKK and sodium chloride (NaCl) powders with mean particle sizes of 70 and 250 μm, respectively, were used as-received. HA whiskers were synthesized using the chelate decomposition method. The as-synthesized HA whiskers were measured by optical microscopy to have a mean length of 21.6 μm, width of μm and aspect ratio of 7.6.
  • In the example, composite scaffolds with 75, 82.5 and 90% porosity were processed with 0-40 vol % HA whisker reinforcement. Appropriate amounts of polymer powder and HA whiskers were co-dispersed in ethanol via a sonic dismembrator and mechanical stirring at 1200 rpm. Following dispersion, the appropriate amount of the NaCl (i.e., porogen) was added to the suspension and mixed by hand using a Teflon coated spatula. The total scaffold volume consisted of the material volume plus the pore volume. Thus, the reinforcement level was calculated based the desired material volume, while the porosity level was calculated based on the total scaffold volume. After mixing, the viscous suspension was wet-consolidated using vacuum filtration. The powder mixture was dried overnight in a forced convection oven at 90° C. and densified at 125 MPa in a cylindrical pellet die using a hydraulic platen press. The die and densified powder mixture was heated in a vacuum oven to the desired processing temperature and transferred to a hydraulic platen press for compression molding. Scaffolds with 82.5 and 90% porosity were molded at 350° C., while scaffolds with 75% porosity were molded at 350, 365 and 375° C. A pressure of 250 MPa was applied to the die as the polymer solidified. After cooling to room temperature, the sintered composite pellet was ejected from the die and placed approximately 300 mL deionized water for at least 72 h to dissolve the NaCl crystals. The deionized water was changed daily. The as-molded composite scaffolds had a diameter of 1 cm and were machined to a height of 1 cm.
  • In the example, un-confined compression tests were performed to investigate the mechanical properties of the composite scaffolds. Specimens were tested on an electromagnetic test instrument in phosphate buffered saline (PBS) at 37° C. using a crosshead speed of 1 mm/min. Force-displacement data was used to calculate the elastic modulus, compressive yield stress (CYS), and failure strain of the composite scaffolds. One-way analysis of variance (ANOVA) was used to compare mechanical properties between experimental groups. The compressive properties of HA whisker reinforced PEKK scaffolds were tabulated in table 1.
  • The table below provides mechanical properties of the example PEKK scaffold reinforced with HA whiskers that was processed using a compression molding/particle leaching method such as, for example, the method 800 of FIG. 8 as implemented in the description above. The mechanical properties of HA whisker reinforced PEKK were evaluated in uniaxial compression. Tensile properties of the HA whisker reinforced PEKK scaffolds were evaluated prior to scaffold fabrication.
  • TABLE 1
    Molding
    HA Temper- Elastic Yield
    Porosity Content ature Modulus CYS Strain
    (%) (Vol %) (° C.) (MPa) (MPa) (%)
    75 0 350 69.5 (12.2) 1.25 (0.16) 5.7 (0.4)
    75 0 365 100.7 (10.7) 2.04 (0.26) 4.4 (1.2)
    75 0 375 95.6 (10.5) 2.55 (0.34) 4.4 (1.1)
    75 20 350 106.3 (15.0) 1.28 (0.13) 3.7 (1.1)
    75 20 365 115.4 (13.4) 1.77 (0.30) 2.9 (0.6)
    75 20 375 141.1 (39.2) 2.28 (0.35) 2.9 (0.7)
    75 40 350 54.0 (18.3) 0.52 (0.17) 2.2 (0.3)
    75 40 365 84.3 (41.5) 1.15 (0.38) 2.7 (0.5)
    75 40 375 120.2 (29.8) 1.65 (0.34) 2.3 (1.9)
    82 40 350 15.7 (6.7) 0.13 (0.03) 2.6 (1.9)
    90 0 350 0.75 (0.18) 0.15 (0.04) 30 (0.0)
    90 40 350 0.23 (0.13) 0.04 (0.01) 30 (0.0)
  • As shown in the table, for a given reinforcement level, the compressive modulus decreased with increased porosity, and the yield strength decreased with increased porosity. Scaffolds with 0% vol % HA whisker reinforcement and 75% and 90% porosity exhibited moduli of 69.5 and 0.75 MPa, while scaffolds with 40 vol % HA whisker reinforcement and 75%, 82% and 90% porosity exhibited moduli of 54.0, 15.7 and 0.23 MPa, respectively.
  • Scaffolds with 0 vol % HA whisker reinforcement and 75% and 90% porosity exhibited yield strengths of 1.25 MPa and 0.15 MPa, respectively. Scaffolds with 40 vol % HA whisker reinforcement and 75%, 82% and 90% porosity exhibited yield strengths of 0.52 MPa, 0.13 MPa and 0.04 MPa, respectively. The HA content also affected the modulus and failure strain of the scaffolds. A scaffold having 75% porosity and 20 vol % reinforcement HA whisker exhibited modulus of 106.3 MPa, compared to a modulus of 69.5 MPa for scaffolds with 0 vol % HA whisker reinforcement.
  • The example methods and apparatus described herein offer synthetic porous composite material that may be used for synthetic bone substitutes for implant fixation, fraction fixation, synthetic bone graft substitutes, interbody spinal fusion, tissue engineering scaffolds, or other applications. Many aspects of the of the porous composite material may be tailored to provide specific mechanical, biological, and surgical functions, such as, the polymer composition and molecular orientation, porosity and pore size of the porous matrix, or the HA reinforcement content, morphology, preferred orientation, and size.
  • Although the teachings of the present disclosure have been illustrated in connection with certain examples, there is no intent to limit the present disclosure to such examples. On the contrary, the intention of this application is to cover all modifications and examples fairly falling within the scope of the appended claims either literally or under the doctrine of equivalents.

Claims (28)

What we claim is:
1. A composite material, comprising:
a porous reinforced composite scaffold, comprising:
a polyaryletherketone polymer and anisometric reinforcement particles distributed throughout the polyaryletherketone polymer, and
a substantially continuously interconnected plurality of pores distributed throughout the polyaryletherketone polymer, each of the pores in the plurality of pores defined by voids interconnected by struts, each pore void having a size within a range from about 10 to 500 μm,
wherein a plurality of the anisometric reinforcement particles are both embedded within the polyaryletherketone polymer and exposed on the struts within the pore voids, and
wherein the porous reinforced composite scaffold has a scaffold volume that includes a material volume defined by the polyaryletherketone polymer and the anisometric reinforcement particles, and a pore volume defined by the plurality of pores.
2. The composite material according to claim 1, wherein the porous reinforced composite scaffold is formed by mixing polymer, reinforcement, and porogen particles to obtain a substantially uniform particle mixture, compression molding the particle mixture, and removing the porogen particles.
3. The composite material according to claim 2, wherein the particle mixture is dispersed in a non-solvating fluid, and wherein the non-solvating fluid is removed by one of vacuum, heating or a combination thereof prior to compression molding.
4. The composite material according to claim 2, wherein each of the pores in the plurality of pores has a pore void size and shape defined by the removed porogen particles, and wherein the porogen particles are either homogenous or heterogeneous in shape and are either homogeneous or heterogeneous in size, the porogen particle size in the range from about 10 to 500 μm.
5. The composite material according to claim 2, wherein the porogen particles are selected from the group consisting of NaCl, wax, polysaccharides, cellulose, and combinations thereof.
6. The composite material according to claim 2, wherein the porogen particles have been removed from the porous reinforced composite scaffold material by leaching.
7. The composite material according to claim 1, wherein the anisometric reinforcement particles are present in the polyaryletherketone polymer from about 1 to about 60% of the material volume.
8. The composite material according to claim 1, wherein the anisometric reinforcement particles are distributed essentially uniformly throughout the polyaryletherketone polymer.
9. The composite material according to claim 1, wherein the anisometric reinforcement particles comprise one or more of hydroxyapatite, calcium-deficient hydroxyapatite, carbonated calcium hydroxyapatite, beta-tricalcium phosphate (beta-TCP), alpha-tricalcium phosphate (alpha-TCP), amorphous calcium phosphate (ACP), octacalcium phosphate (OCP), tetracalcium phosphate, biphasic calcium phosphate (BCP), anhydrous dicalcium phosphate (DCPA), dicalcium phosphate dihydrate (DCPD), anhydrous monocalcium phosphate (MCPA), monocalcium phosphate monohydrate (MCPM), and combinations thereof, and, wherein the polyaryletherketone polymer comprises one or more of polyetheretherketone (PEEK), polyetherketonekteone (PEKK), and polyetherketone (PEK).
10. The composite material according to claim 1, wherein the anisometric reinforcement particles comprise hydroxyapatite whiskers that have a mean aspect ratio (length along c-axis/length along a-axis) of greater than 1 and less than 100, and wherein the size of the anisometric reinforcement particles ranges between 20 nm and 2 mm.
11. The composite material according to claim 1, wherein the pore volume ranges from about 1 to 95 percent, by volume, based on the scaffold volume.
12. The composite material according to claim 1, wherein the porosity varies within the porous reinforced composite scaffold either from a highly porous center to a relatively dense exterior surface or from a relatively dense center to a highly porous exterior surface.
13. The composite material according to claim 1, wherein the porous reinforced composite scaffold has a compressive elastic modulus similar to that of trabecular bone.
14. A composite material, comprising:
a porous reinforced composite scaffold, comprising:
a polyaryletherketone polymer and anisometric reinforcement particles comprising calcium phosphate crystals distributed essentially uniformly throughout the polyaryletherketone polymer, and
a substantially continuously interconnected plurality of pores that are uniformly distributed throughout the polyaryletherketone polymer, each of the pores in the plurality of pores defined by voids interconnected by struts, each pore void having a size within a range from about 10 to 500 μm, and
wherein the porous reinforced composite scaffold has a scaffold volume that includes a material volume defined by the polyaryletherketone polymer and the anisometric reinforcement particles, and a pore volume defined by the plurality of pores, and
wherein the anisometric reinforcement particles are present in the polyaryletherketone polymer from about 1 to about 60% of the material volume, and
wherein anisometric reinforcement particles are both embedded within the polyaryletherketone polymer and exposed on the struts within the pore voids, and
wherein the porous reinforced composite scaffold is formed by mixing polymer, reinforcement, and porogen particles to obtain a substantially uniform mixture, compression molding the particle mixture at a temperature from between 20 to 400 degrees C., and removing the porogen particles.
15. The composite material according to claim 14, wherein the particle mixture is dispersed in a non-solvating fluid, and wherein the non-solvating fluid is removed by one of vacuum, heating or a combination thereof prior to compression molding.
16. The composite material according to claim 14, wherein the compression molding temperature is in a range from about 350 to about 375 degrees C.
17. The composite material according to claim 14, wherein the compression molding temperature is in a range from about 365 to about 375 degrees C.
18. A method for forming a porous reinforced composite scaffold, comprising:
using a powder processing approach in conjunction with compression molding and particle leaching to prepare the composite scaffold, the process including the steps comprising:
providing a powder mixture densified in a die, the powder mixture comprising a thermoplastic polymer powder, reinforcement particles in powder form, and porogen particles;
compression molding the densified powder mixture at a temperature sufficient to fuse the polymer powder to provide a sintered composite; and
removing the porogen particles a material from the porous reinforced composite scaffold.
19. The method for forming a porous reinforced composite scaffold according to claim 18, further comprising the steps comprising;
prior to providing the powder mixture densified in a die, first providing each of the thermoplastic polymer powder, the reinforcement particles in powder form, and the porogen particles;
dispersing, in any order, each of the thermoplastic polymer powder, the reinforcement particles in powder form, and the porogen particles in a non-solvating fluid to provide a fluid dispersion of the powder mixture;
wet-consolidating the powder mixture to remove the fluid; and
drying the wet-consolidated powder mixture.
20. The method for forming a porous reinforced composite scaffold according to claim 18, wherein the compression molding temperature sufficient to fuse the polymer powder is in a range from about 350 to about 375 degrees C.
21. The method for forming a porous reinforced composite scaffold according to claim 18, wherein the compression molding temperature sufficient to fuse the polymer powder is in a range from about 365 to about 375 degrees C.
22. The method for forming a porous reinforced composite scaffold according to claim 18, wherein the thermoplastic polymer powder comprises a polyaryletherketone polymer, and wherein the reinforcement particles comprise anisometric calcium phosphate.
23. A composite material, comprising:
a porous reinforced composite scaffold, comprising:
a thermoplastic polymer and reinforcement particles distributed throughout the thermoplastic polymer, and
a substantially continuously interconnected plurality of pores that are distributed throughout the thermoplastic polymer, each of the pores in the plurality of pores defined by voids interconnected by struts, each pore void having a size within a range from about 10 to 500 μm, and
wherein the porous reinforced composite scaffold has a scaffold volume that includes a material volume defined by the thermoplastic polymer and the reinforcement particles, and a pore volume defined by the plurality of pores, and
wherein the reinforcement particles are present in the thermoplastic polymer from about 1 to about 60% of the material volume, and
wherein reinforcement particles are both embedded within the thermoplastic polymer and exposed on the struts within the pore voids.
24. The composite material according to claim 23, wherein the porous reinforced composite scaffold is formed by mixing thermoplastic polymer, reinforcement, and porogen particles to obtain a substantially uniform mixture, compression molding the particle mixture at a temperature from between 20 to 400 degrees C., and removing the porogen particles.
25. The composite material according to claim 23, wherein the thermoplastic polymer is selected from the group consisting of a polyaryletherketone polymer, a bioresorbable polymer, and combinations thereof.
26. The composite material according to claim 23, wherein the thermoplastic polymer is selected from the group consisting of polyaryletherketone (PAEK), polyetheretherketone (PEEK), polyetherketonekteone (PEKK), polyetherketone (PEK), polyethylene, high density polyethylene (HDPE), ultra-high molecular weight polyethylene (UHMWPE), low density polyethylene (LDPE), polyethylene oxide (PEO), polyurethane, polypropylene, polypropylene oxide (PPO), polysulfone, polypropylene, poly(DL-lactide) (PDLA), poly(L-lactide) (PLLA), poly(glycolide) (PGA), poly(c-caprolactone) (PCL), poly(dioxanone) (PDO), poly(glyconate), poly(hydroxybutyrate) (PHB), poly(hydroxyvalerate (PHV), poly(orthoesters), poly(carboxylates), poly(propylene fumarate), poly(phosphates), poly(carbonates), poly(anhydrides), poly(iminocarbonates), poly(phosphazenes), polymethylmethacrylate (PMMA), bisphenol a hydroxypropylmethacrylate (bis-GMA), tri(ethylene glycol) dimethacrylate (TEG-DMA), and combinations thereof.
27. The composite material according to claim 23, wherein the reinforcement is selected from the group consisting of hydroxyapatite, calcium-deficient hydroxyapatite, carbonated calcium hydroxyapatite, beta-tricalcium phosphate (beta-TCP), alpha-tricalcium phosphate (alpha-TCP), amorphous calcium phosphate (ACP), octacalcium phosphate (OCP), tetracalcium phosphate, biphasic calcium phosphate (BCP), anhydrous dicalcium phosphate (DCPA), dicalcium phosphate dihydrate (DCPD), anhydrous monocalcium phosphate (MCPA), monocalcium phosphate monohydrate (MCPM), and combinations thereof.
28. The composite material according to claim 23, wherein the thermoplastic polymer comprises a polyaryletherketone polymer, and wherein the reinforcement comprises anisometric calcium phosphate.
US17/180,935 2007-02-28 2021-02-22 Porous composite biomaterials and related methods Abandoned US20210177620A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US17/180,935 US20210177620A1 (en) 2007-02-28 2021-02-22 Porous composite biomaterials and related methods
US17/519,336 US20220062004A1 (en) 2007-02-28 2021-11-04 Porous composite biomaterials and related methods

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US90409807P 2007-02-28 2007-02-28
US93925607P 2007-05-21 2007-05-21
US12/039,666 US20080206297A1 (en) 2007-02-28 2008-02-28 Porous composite biomaterials and related methods
US14/078,614 US10945854B2 (en) 2007-02-28 2013-11-13 Porous composite biomaterials and related methods
US17/180,935 US20210177620A1 (en) 2007-02-28 2021-02-22 Porous composite biomaterials and related methods

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/078,614 Continuation US10945854B2 (en) 2007-02-28 2013-11-13 Porous composite biomaterials and related methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/519,336 Continuation US20220062004A1 (en) 2007-02-28 2021-11-04 Porous composite biomaterials and related methods

Publications (1)

Publication Number Publication Date
US20210177620A1 true US20210177620A1 (en) 2021-06-17

Family

ID=39716166

Family Applications (4)

Application Number Title Priority Date Filing Date
US12/039,666 Abandoned US20080206297A1 (en) 2007-02-28 2008-02-28 Porous composite biomaterials and related methods
US14/078,614 Active 2028-06-06 US10945854B2 (en) 2007-02-28 2013-11-13 Porous composite biomaterials and related methods
US17/180,935 Abandoned US20210177620A1 (en) 2007-02-28 2021-02-22 Porous composite biomaterials and related methods
US17/519,336 Pending US20220062004A1 (en) 2007-02-28 2021-11-04 Porous composite biomaterials and related methods

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US12/039,666 Abandoned US20080206297A1 (en) 2007-02-28 2008-02-28 Porous composite biomaterials and related methods
US14/078,614 Active 2028-06-06 US10945854B2 (en) 2007-02-28 2013-11-13 Porous composite biomaterials and related methods

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/519,336 Pending US20220062004A1 (en) 2007-02-28 2021-11-04 Porous composite biomaterials and related methods

Country Status (2)

Country Link
US (4) US20080206297A1 (en)
WO (1) WO2008106625A2 (en)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558426B1 (en) 2000-11-28 2003-05-06 Medidea, Llc Multiple-cam, posterior-stabilized knee prosthesis
GB0329654D0 (en) 2003-12-23 2004-01-28 Smith & Nephew Tunable segmented polyacetal
EP1988855A2 (en) 2006-02-27 2008-11-12 Synthes GmbH Intervertebral implant with fixation geometry
US20110282392A1 (en) * 2006-10-30 2011-11-17 Tissue Regeneration Systems, Inc. Degradable cage for bone fusion
DE602007011671D1 (en) 2006-11-30 2011-02-10 Smith & Nephew Inc FIBER REINFORCED COMPOSITE MATERIAL
US11179243B2 (en) 2007-02-28 2021-11-23 Happe Spine Llc Implantable devices
US20080206297A1 (en) 2007-02-28 2008-08-28 Roeder Ryan K Porous composite biomaterials and related methods
EP2142353A1 (en) 2007-04-18 2010-01-13 Smith & Nephew PLC Expansion moulding of shape memory polymers
JP5680957B2 (en) 2007-04-19 2015-03-04 スミス アンド ネフュー インコーポレーテッドSmith & Nephew,Inc. Graft fixation
JP5520814B2 (en) 2007-04-19 2014-06-11 スミス アンド ネフュー インコーポレーテッド Multimodal shape memory polymer
US20110035017A1 (en) * 2007-09-25 2011-02-10 Depuy Products, Inc. Prosthesis with cut-off pegs and surgical method
US8632600B2 (en) 2007-09-25 2014-01-21 Depuy (Ireland) Prosthesis with modular extensions
US8128703B2 (en) 2007-09-28 2012-03-06 Depuy Products, Inc. Fixed-bearing knee prosthesis having interchangeable components
US8715359B2 (en) 2009-10-30 2014-05-06 Depuy (Ireland) Prosthesis for cemented fixation and method for making the prosthesis
US9204967B2 (en) 2007-09-28 2015-12-08 Depuy (Ireland) Fixed-bearing knee prosthesis having interchangeable components
CA2711403C (en) * 2008-02-01 2016-08-09 Synthes Usa, Llc Porous biocompatible polymer material and methods
US9168145B2 (en) 2008-06-30 2015-10-27 Depuy (Ireland) Posterior stabilized orthopaedic knee prosthesis having controlled condylar curvature
US8187335B2 (en) 2008-06-30 2012-05-29 Depuy Products, Inc. Posterior stabilized orthopaedic knee prosthesis having controlled condylar curvature
US8828086B2 (en) 2008-06-30 2014-09-09 Depuy (Ireland) Orthopaedic femoral component having controlled condylar curvature
US9119723B2 (en) 2008-06-30 2015-09-01 Depuy (Ireland) Posterior stabilized orthopaedic prosthesis assembly
US8192498B2 (en) 2008-06-30 2012-06-05 Depuy Products, Inc. Posterior cructiate-retaining orthopaedic knee prosthesis having controlled condylar curvature
US8236061B2 (en) 2008-06-30 2012-08-07 Depuy Products, Inc. Orthopaedic knee prosthesis having controlled condylar curvature
US8206451B2 (en) 2008-06-30 2012-06-26 Depuy Products, Inc. Posterior stabilized orthopaedic prosthesis
EP2349107B1 (en) 2008-08-14 2016-12-21 Oxford Performance Materials, Inc. Customized implants for bone replacement
CN102256570B (en) * 2008-11-07 2015-09-02 斯恩蒂斯有限公司 The interpyramidal distance piece of vertebra and connecting plate assembly
WO2010091223A1 (en) * 2009-02-06 2010-08-12 David Cheung Biphasic collagen membrane or capsule for guided tissue regeneration
US20100256758A1 (en) * 2009-04-02 2010-10-07 Synvasive Technology, Inc. Monolithic orthopedic implant with an articular finished surface
US8609127B2 (en) * 2009-04-03 2013-12-17 Warsaw Orthopedic, Inc. Medical implant with bioactive material and method of making the medical implant
US9492587B2 (en) * 2009-04-13 2016-11-15 Abbott Cardiovascular Systems Inc. Stent made from an ultra high molecular weight bioabsorbable polymer with high fatigue and fracture resistance
US20100262244A1 (en) * 2009-04-14 2010-10-14 Warsaw Orthopedic, Inc. Metal Coated Implant
US9399086B2 (en) 2009-07-24 2016-07-26 Warsaw Orthopedic, Inc Implantable medical devices
US9039784B2 (en) * 2009-07-28 2015-05-26 Southwest Research Institute Micro-structure particles for load bearing bone growth
EP2606857A1 (en) 2009-10-30 2013-06-26 DePuy Products, Inc. Prosthesis with composite component
US9011547B2 (en) 2010-01-21 2015-04-21 Depuy (Ireland) Knee prosthesis system
KR101196062B1 (en) 2010-05-03 2012-11-01 순천향대학교 산학협력단 Method for preparing porous biphasic calciumphosphate granules
EP2621869A4 (en) * 2010-10-01 2014-10-08 Skeletal Kinetics Llc Porogen containing calcium phosphate cement compositions
US9339387B2 (en) 2010-10-13 2016-05-17 Cibor, Inc. Synthetic bone grafts constructed from carbon foam materials
US8998987B2 (en) 2010-11-11 2015-04-07 Zimmer, Inc. Orthopedic implant with porous polymer bone contacting surface
WO2012088238A2 (en) 2010-12-21 2012-06-28 Synthes Usa, Llc Intervertebral implants, systems, and methods of use
WO2012099852A1 (en) 2011-01-17 2012-07-26 Cibor, Inc. Reinforced carbon fiber/carbon foam intervertebral spine fusion device
GB201100815D0 (en) * 2011-01-18 2011-03-02 Invibio Ltd Polymeric materials
GB2488111A (en) * 2011-02-14 2012-08-22 Invibio Ltd Components incorporating bioactive material
DE102011004305A1 (en) * 2011-02-17 2012-08-23 Evonik Degussa Gmbh Process for the production of bars
JP5955326B2 (en) * 2011-08-30 2016-07-20 国立大学法人京都大学 Porous scaffold material and method for producing the same
CN103959359A (en) * 2011-10-03 2014-07-30 克利夫兰临床医学基金会 Synthetic bone model and method for providing same
DE102011119939A1 (en) * 2011-12-01 2013-06-06 Technische Universität Hamburg-Harburg Method of making a composite, the composite and the use of the composite to make certain products
US11304811B2 (en) 2012-01-17 2022-04-19 KYOCERA Medical Technologies, Inc. Surgical implant devices incorporating porous surfaces and associated method of manufacture
KR20150015532A (en) * 2012-05-30 2015-02-10 뉴욕 유니버시티 Tissue repair devices and scaffolds
US10207027B2 (en) 2012-06-11 2019-02-19 Globus Medical, Inc. Bioactive bone graft substitutes
CN102727937B (en) * 2012-06-28 2014-03-26 哈尔滨工程大学 Biodegradable zinc (or zinc alloy) and porous biphase calcium phosphate composite material and preparation method thereof
US8843229B2 (en) * 2012-07-20 2014-09-23 Biomet Manufacturing, Llc Metallic structures having porous regions from imaged bone at pre-defined anatomic locations
EP3431271B1 (en) 2012-08-21 2020-08-05 Vertera Inc. Method of forming porous polymeric particulates
US9949837B2 (en) * 2013-03-07 2018-04-24 Howmedica Osteonics Corp. Partially porous bone implant keel
US20140342013A1 (en) * 2013-03-14 2014-11-20 Skeletal Kinetics, Llc Calcium phosphate cement compositions that set into high strength porous structures
EP3024419B1 (en) * 2013-07-24 2022-05-11 Kyocera Medical Technologies, Inc. Surgical implant devices incorporating porous surfaces
WO2015013479A2 (en) 2013-07-24 2015-01-29 Renovis Surgical Technologies, Inc. Surgical implant devices incorporating porous surfaces
US9550012B2 (en) 2013-08-05 2017-01-24 University Of Notre Dame Du Lac Tissue scaffolds having bone growth factors
US9295565B2 (en) 2013-10-18 2016-03-29 Spine Wave, Inc. Method of expanding an intradiscal space and providing an osteoconductive path during expansion
US9504550B2 (en) 2014-06-26 2016-11-29 Vertera, Inc. Porous devices and processes for producing same
US9498922B2 (en) 2014-06-26 2016-11-22 Vertera, Inc. Apparatus and process for producing porous devices
JP6871855B2 (en) * 2014-10-14 2021-05-19 サムエル リンチ, Composition for treating wounds
US9867718B2 (en) 2014-10-22 2018-01-16 DePuy Synthes Products, Inc. Intervertebral implants, systems, and methods of use
US10279081B2 (en) 2014-10-24 2019-05-07 Allosource Composite grafts, systems, and methods
US20160167306A1 (en) * 2014-12-11 2016-06-16 Massachusetts Institute Of Technology Systems and methods of hierarchical material design for additive fabrication
US9821339B2 (en) * 2014-12-19 2017-11-21 Palo Alto Research Center Incorporated System and method for digital fabrication of graded, hierarchical material structures
US9486960B2 (en) 2014-12-19 2016-11-08 Palo Alto Research Center Incorporated System for digital fabrication of graded, hierarchical material structures
WO2016105286A1 (en) * 2014-12-25 2016-06-30 Hasirci Vasif Nejat A new prosthesis material developed for use in the treatment of cervical and lumbar disc hernia
EP3240584A1 (en) * 2014-12-29 2017-11-08 Hasirci, Vasif Nejat Craniofacial implants
CN104623728B (en) * 2015-01-12 2016-05-11 四川大学 Anisotropy bone replacement composites of a kind of injection mo(u)lding and preparation method thereof
AU2016219150B2 (en) * 2015-02-13 2020-06-25 Eit Emerging Implant Technologies Gmbh Spinal implants with engineered cellular structure and internal imaging markers
USD815281S1 (en) 2015-06-23 2018-04-10 Vertera, Inc. Cervical interbody fusion device
FR3039988A1 (en) * 2015-08-11 2017-02-17 Abdelmadjid Djemai EXPANDED SPRING INTERSOMATIC CAGE, DOUBLE-STRUCKED DOUBLE STRUCK HINGE AND METHOD FOR MANUFACTURING THE SAME
US10485897B2 (en) * 2015-10-12 2019-11-26 Erik Erbe Osteogenic and angiogenic implant material
CN105233335B (en) * 2015-11-06 2018-07-13 四川大学 Biologically active porous poly(aryl ether ketone) material of one kind and the preparation method and application thereof
US10596660B2 (en) * 2015-12-15 2020-03-24 Howmedica Osteonics Corp. Porous structures produced by additive layer manufacturing
EP3389570B1 (en) * 2015-12-16 2024-04-17 Nuvasive, Inc. Porous spinal fusion implant
CN106913406A (en) * 2015-12-25 2017-07-04 苏州微创脊柱创伤医疗科技有限公司 A kind of spinal fusion device and preparation method thereof
CN105559950B (en) * 2016-02-03 2018-02-02 北京纳通科技集团有限公司 Fusion device
AU2017232908A1 (en) * 2016-03-18 2018-10-11 Allosource Composite medical grafts and methods of use and manufacture
US20190076577A1 (en) * 2016-03-18 2019-03-14 Allosource Composite medical grafts and methods of use and manufacture
DE102016107223B4 (en) * 2016-04-19 2018-05-24 Karl Leibinger Medizintechnik Gmbh & Co. Kg Hybrid implant made of a composite material
US11638645B2 (en) 2016-05-19 2023-05-02 University of Pittsburgh—of the Commonwealth System of Higher Education Biomimetic plywood motifs for bone tissue engineering
US10806586B2 (en) * 2016-05-19 2020-10-20 University Of Pittsburgh—Of The Commonwealth System Of Higer Education Biomimetic plywood motifs for bone tissue engineering
US10660764B2 (en) * 2016-06-14 2020-05-26 The Trustees Of The Stevens Institute Of Technology Load sustaining bone scaffolds for spinal fusion utilizing hyperbolic struts and translational strength gradients
FI127762B (en) * 2016-09-19 2019-02-15 Tty Saeaetioe Method for producing porous composite material
US11033394B2 (en) * 2016-10-25 2021-06-15 Institute for Musculoskeletal Science and Education, Ltd. Implant with multi-layer bone interfacing lattice
CN106344221A (en) * 2016-10-26 2017-01-25 四川大学 Bonelike porous biomechanical bionic designed spinal fusion device and preparation method and use thereof
CN106435544A (en) * 2016-11-09 2017-02-22 北京科技大学 Method for preparing nano-hydroxyapatite gradient coating on titanium alloy matrix
US11685113B2 (en) * 2017-03-06 2023-06-27 Katholieke Universiteit Leuven 3D printing of porous liquid handling device
GB2560369B (en) * 2017-03-10 2020-04-01 Vestlandets Innovasjonsselskap As Tissue engineering scaffolds
WO2018165571A1 (en) * 2017-03-10 2018-09-13 Life Spine, Inc. (A Delaware Corporation) 3-d printed orthopedic implants
US10064726B1 (en) 2017-04-18 2018-09-04 Warsaw Orthopedic, Inc. 3D printing of mesh implants for bone delivery
US20180296343A1 (en) * 2017-04-18 2018-10-18 Warsaw Orthopedic, Inc. 3-d printing of porous implants
US11660196B2 (en) 2017-04-21 2023-05-30 Warsaw Orthopedic, Inc. 3-D printing of bone grafts
US20180339082A1 (en) * 2017-05-23 2018-11-29 Bioalpha Corporation Polyether ether ketone surface-modified with hydroxyapatite
CN107320220B (en) * 2017-06-14 2019-12-24 西安交通大学 Preparation method of porous implant based on ceramic additive manufacturing
US11628517B2 (en) 2017-06-15 2023-04-18 Howmedica Osteonics Corp. Porous structures produced by additive layer manufacturing
EP3479798B1 (en) 2017-11-03 2023-06-21 Howmedica Osteonics Corp. Flexible construct for femoral reconstruction
US10713238B2 (en) * 2017-11-14 2020-07-14 Snowflake Inc. Database metadata in immutable storage
CN108309517B (en) * 2018-01-25 2019-08-30 中国人民解放军新疆军区总医院 A kind of absorbable cervical fusion cage and preparation method thereof
USD870888S1 (en) 2018-03-02 2019-12-24 Restor3D, Inc. Accordion airway stent
USD870889S1 (en) 2018-03-02 2019-12-24 Restor3D, Inc. Cutout airway stent
USD870890S1 (en) 2018-03-02 2019-12-24 Restor3D, Inc. Spiral airway stent
US10183442B1 (en) 2018-03-02 2019-01-22 Additive Device, Inc. Medical devices and methods for producing the same
USD871577S1 (en) 2018-03-02 2019-12-31 Restor3D, Inc. Studded airway stent
WO2019191149A1 (en) * 2018-03-26 2019-10-03 The Regents Of The University Of California Medical implants and other articles of manufacture based on trabecular bone lattices
US10947419B2 (en) 2018-07-23 2021-03-16 Palo Alto Research Center Incorporated Method for joining dissimilar materials
WO2020060809A1 (en) * 2018-09-17 2020-03-26 Rejuvablast LLC Combination grafts for tissue repair or regeneration applications
WO2020061176A1 (en) * 2018-09-18 2020-03-26 Happe Spine Llc Implantable devices
US11607476B2 (en) 2019-03-12 2023-03-21 Happe Spine Llc Implantable medical device with thermoplastic composite body and method for forming thermoplastic composite body
US10889053B1 (en) 2019-03-25 2021-01-12 Restor3D, Inc. Custom surgical devices and method for manufacturing the same
USD920517S1 (en) 2020-01-08 2021-05-25 Restor3D, Inc. Osteotomy wedge
USD920515S1 (en) 2020-01-08 2021-05-25 Restor3D, Inc. Spinal implant
US10772732B1 (en) 2020-01-08 2020-09-15 Restor3D, Inc. Sheet based triply periodic minimal surface implants for promoting osseointegration and methods for producing same
USD920516S1 (en) 2020-01-08 2021-05-25 Restor3D, Inc. Osteotomy wedge
CN112060574B (en) * 2020-07-21 2022-03-29 陈勃生 Additive manufacturing method of three-dimensional implant made of biological composite material
EP4210922A1 (en) 2020-09-11 2023-07-19 Happe Spine LLC Method for forming an implantable medical device with varied composition and porosity
EP3984715B1 (en) * 2020-10-13 2023-11-15 Technische Universität München Fiber-reinforced soluble core and method for its manufacture
EP3984501A1 (en) * 2020-10-14 2022-04-20 Warsaw Orthopedic, Inc. Additive-manufactured non-woven fibrous implants, systems, and related manufacturing methods
US20220203589A1 (en) * 2020-12-24 2022-06-30 Next Chapter Manufacturing Corporation Vented Mold Pin
US20220296780A1 (en) * 2021-03-16 2022-09-22 Orthomod Llc Bioceramic-containing thermoplastic extrusion and method of surgical implant manufacture
CN113103576B (en) * 2021-04-07 2022-01-28 吉林大学 3D printing method for ordered gradient porous material
CN113842499B (en) * 2021-09-17 2022-07-01 中国科学院宁波材料技术与工程研究所 Ultrahigh molecular weight polyethylene composite material and preparation method and application thereof
WO2023137124A2 (en) * 2022-01-12 2023-07-20 Orthofundamentals, Llc Medical implants for generating fusion between two bones
CN115120781A (en) * 2022-07-11 2022-09-30 运怡(北京)医疗器械有限公司 Medical composite high polymer material and preparation method thereof
US11850144B1 (en) 2022-09-28 2023-12-26 Restor3D, Inc. Ligament docking implants and processes for making and using same
US11806028B1 (en) 2022-10-04 2023-11-07 Restor3D, Inc. Surgical guides and processes for producing and using the same
EP4353168A1 (en) * 2022-10-12 2024-04-17 Kumovis GmbH 3d printed semi-finished part for medical implant manufacturing and medical implant thereof
US11960266B1 (en) 2023-08-23 2024-04-16 Restor3D, Inc. Patient-specific medical devices and additive manufacturing processes for producing the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115742A1 (en) * 2001-02-22 2002-08-22 Trieu Hai H. Bioactive nanocomposites and methods for their use

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514378A (en) * 1993-02-01 1996-05-07 Massachusetts Institute Of Technology Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures
US6689608B1 (en) * 1993-02-01 2004-02-10 Massachusetts Institute Of Technology Porous biodegradable polymeric materials for cell transplantation
US5522895A (en) * 1993-07-23 1996-06-04 Rice University Biodegradable bone templates
US5626861A (en) * 1994-04-01 1997-05-06 Massachusetts Institute Of Technology Polymeric-hydroxyapatite bone composite
WO1997010010A1 (en) * 1995-09-14 1997-03-20 Takiron Co., Ltd. Osteosynthetic material, composited implant material, and process for preparing the same
US5866155A (en) * 1996-11-20 1999-02-02 Allegheny Health, Education And Research Foundation Methods for using microsphere polymers in bone replacement matrices and composition produced thereby
US6472210B1 (en) * 1997-11-14 2002-10-29 Bonetec Corporation Polymer scaffold having microporous polymer struts defining interconnected macropores
US7022522B2 (en) * 1998-11-13 2006-04-04 Limin Guan Macroporous polymer scaffold containing calcium phosphate particles
US6306424B1 (en) * 1999-06-30 2001-10-23 Ethicon, Inc. Foam composite for the repair or regeneration of tissue
US6333029B1 (en) * 1999-06-30 2001-12-25 Ethicon, Inc. Porous tissue scaffoldings for the repair of regeneration of tissue
US6355699B1 (en) * 1999-06-30 2002-03-12 Ethicon, Inc. Process for manufacturing biomedical foams
WO2001028469A2 (en) * 1999-10-21 2001-04-26 Sdgi Holdings, Inc. Devices and techniques for a posterior lateral disc space approach
US7758882B2 (en) * 2000-01-31 2010-07-20 Indiana University Research And Technology Corporation Composite biomaterial including anisometric calcium phosphate reinforcement particles and related methods
AU2001261465A1 (en) * 2000-05-12 2001-11-26 The Regents Of The University Of Michigan Reverse fabrication of porous materials
US6423252B1 (en) * 2000-06-23 2002-07-23 Ethicon, Inc. Methods of making micropatterned foams
JP2004501719A (en) * 2000-07-03 2004-01-22 オステオテック インコーポレーテッド Osteogenic implants derived from bone
US6595998B2 (en) * 2001-03-08 2003-07-22 Spinewave, Inc. Tissue distraction device
US20050177238A1 (en) * 2001-05-01 2005-08-11 Khandkar Ashok C. Radiolucent bone graft
US6987136B2 (en) * 2001-07-13 2006-01-17 Vita Special Purpose Corporation Bioactive spinal implant material and method of manufacture thereof
US7037339B2 (en) * 2001-09-27 2006-05-02 Zimmer Spine, Inc. Modular spinal fusion device
US6712850B2 (en) * 2001-11-30 2004-03-30 Ethicon, Inc. Porous tissue scaffolds for the repair and regeneration of dermal tissue
EP1344538A1 (en) * 2002-03-14 2003-09-17 Degradable Solutions AG Porous biodegradable implant material and method for its fabrication
US6991653B2 (en) * 2002-03-21 2006-01-31 Sdgi Holdings, Inc. Vertebral body and disc space replacement devices
US6758862B2 (en) * 2002-03-21 2004-07-06 Sdgi Holdings, Inc. Vertebral body and disc space replacement devices
US20040002770A1 (en) * 2002-06-28 2004-01-01 King Richard S. Polymer-bioceramic composite for orthopaedic applications and method of manufacture thereof
US7049348B2 (en) * 2002-07-06 2006-05-23 Kensey Nash Corporation Resorbable structure for treating and healing of tissue defects
US20050251267A1 (en) 2004-05-04 2005-11-10 John Winterbottom Cell permeable structural implant
US20040193270A1 (en) * 2003-03-31 2004-09-30 Depuyacromed, Inc. Implantable bone graft
US6887408B2 (en) * 2003-05-05 2005-05-03 Porogen Llc Porous poly(aryl ether ketone) membranes, processes for their preparation and use thereof
WO2005032418A2 (en) 2003-10-01 2005-04-14 University Of Washington Novel porous biomaterials
US20050100578A1 (en) 2003-11-06 2005-05-12 Schmid Steven R. Bone and tissue scaffolding and method for producing same
US7837732B2 (en) * 2003-11-20 2010-11-23 Warsaw Orthopedic, Inc. Intervertebral body fusion cage with keels and implantation methods
US20050149192A1 (en) * 2003-11-20 2005-07-07 St. Francis Medical Technologies, Inc. Intervertebral body fusion cage with keels and implantation method
US7666230B2 (en) * 2003-12-08 2010-02-23 Depuy Products, Inc. Implant device for cartilage regeneration in load bearing articulation regions
US7137997B2 (en) * 2003-12-29 2006-11-21 Globus Medical, Inc. Spinal fusion implant
US7189263B2 (en) * 2004-02-03 2007-03-13 Vita Special Purpose Corporation Biocompatible bone graft material
US7905920B2 (en) * 2004-08-19 2011-03-15 Foster-Miller, Inc. Support system for intervertebral fusion
US7176273B2 (en) * 2004-11-03 2007-02-13 Porogen Llc Functionalized porous poly(aryl ether ketone) materials and their use
US7780732B2 (en) * 2005-03-16 2010-08-24 Dennis Lee Abernathie Spinal fusion cage and method of use
US8057548B2 (en) * 2005-03-16 2011-11-15 Dennis Lee Abernathie Spinal fusion cage, method of design, and method of use
WO2006113642A1 (en) 2005-04-18 2006-10-26 Duke University Three-dimensional fiber scaffolds for tissue engineering
US7687098B1 (en) 2005-08-26 2010-03-30 Charlie W. Chi Chemical mechanical vapor deposition device for production of bone substitute material
CA2627895C (en) 2005-11-04 2014-10-14 Ppd Meditech Porous material and method for fabricating same
GB0604061D0 (en) 2006-03-01 2006-04-12 Invibio Ltd Polymetric materials
DE102006041023B4 (en) 2006-09-01 2014-06-12 Biocer Entwicklungs Gmbh Structured coatings for implants and process for their preparation
CA2667000A1 (en) 2006-09-25 2008-04-03 James P. Murphy Bioactive load-bearing composites comprising peek and bioglass particles
US20080161927A1 (en) * 2006-10-18 2008-07-03 Warsaw Orthopedic, Inc. Intervertebral Implant with Porous Portions
US20080206297A1 (en) 2007-02-28 2008-08-28 Roeder Ryan K Porous composite biomaterials and related methods
CA2680586A1 (en) 2007-03-26 2008-10-02 Mei Wei Electrospun apatite/polymer nano-composite scaffolds
US20110035018A1 (en) 2007-09-25 2011-02-10 Depuy Products, Inc. Prosthesis with composite component
WO2009095960A1 (en) 2008-01-28 2009-08-06 Ngk Spark Plug Co., Ltd. Surface foamed article, biological implant and method of producing the same
CA2711403C (en) 2008-02-01 2016-08-09 Synthes Usa, Llc Porous biocompatible polymer material and methods
GB0813093D0 (en) 2008-07-17 2008-08-27 Invibio Ltd Polymeric materials
WO2010009390A2 (en) 2008-07-18 2010-01-21 North Carolina State University Processing of biocompatible coating on polymeric implants
GB0818156D0 (en) 2008-10-03 2008-11-12 Smith & Nephew Orthopaedics Ag Plasma spray process and products formed thereby
GB0819055D0 (en) 2008-10-17 2008-11-26 Invibio Ltd Polymeric materials
US20100145393A1 (en) 2008-12-05 2010-06-10 Medicinelodge, Inc. Medical and dental porous implants
US20100168798A1 (en) 2008-12-30 2010-07-01 Clineff Theodore D Bioactive composites of polymer and glass and method for making same
US8609127B2 (en) 2009-04-03 2013-12-17 Warsaw Orthopedic, Inc. Medical implant with bioactive material and method of making the medical implant
GB2469991B (en) 2009-04-21 2013-08-07 Invibio Ltd Polymeric materials
CA2762903C (en) 2009-05-22 2013-07-30 Soft Tissue Regeneration, Inc. Mechanically competent scaffold for ligament and tendon regeneration
DE102009026622A1 (en) 2009-05-29 2010-12-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Shaped bodies with embedded coupling particles for biomolecules
US9399086B2 (en) 2009-07-24 2016-07-26 Warsaw Orthopedic, Inc Implantable medical devices
US8226725B2 (en) 2009-09-01 2012-07-24 Howmedica Osteonics Corp. Prosthesis having a soft tissue attachment element
EP2338532B1 (en) 2009-12-23 2018-01-10 Fundacion Inasmet Porous PEEK article as an implant
GB201005122D0 (en) 2010-03-26 2010-05-12 Invibio Ltd Medical device
GB2488111A (en) 2011-02-14 2012-08-22 Invibio Ltd Components incorporating bioactive material
GB201104805D0 (en) 2011-03-22 2011-05-04 Invibio Ltd Medical device
GB201110729D0 (en) 2011-06-24 2011-08-10 Invibio Ltd Polymeric materials
GB201120375D0 (en) 2011-11-25 2012-01-11 Invibio Ltd Prosthodontic device
GB201219686D0 (en) 2012-11-01 2012-12-12 Invibio Ltd Orthopaedic polymer-on-polymer bearings
US8829096B2 (en) 2013-02-08 2014-09-09 Invibio Limited Polymeric materials

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020115742A1 (en) * 2001-02-22 2002-08-22 Trieu Hai H. Bioactive nanocomposites and methods for their use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Goldstein, S., J. Biomechanics 20(11): 1055 – 1066 (1987). (Year: 1987) *

Also Published As

Publication number Publication date
US20210015977A9 (en) 2021-01-21
US20080206297A1 (en) 2008-08-28
US20220062004A1 (en) 2022-03-03
WO2008106625A3 (en) 2009-12-30
WO2008106625A2 (en) 2008-09-04
US10945854B2 (en) 2021-03-16
US20140236299A1 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
US20210177620A1 (en) Porous composite biomaterials and related methods
US11179243B2 (en) Implantable devices
US11911535B2 (en) Implantable medical device with thermoplastic composite body and method for forming thermoplastic composite body
US8715286B2 (en) Porous and nonporous materials for tissue grafting and repair
EP1024841B1 (en) Bone substitutes
EP1357863B1 (en) Compositions and methods for biomedical applications
US20150265745A1 (en) Porous and Nonporous Materials for Tissue Grafting and Repair
WO2020061176A1 (en) Implantable devices
US10105207B2 (en) Porous and nonporous materials for tissue grafting and repair
Dunkley The Development and Characterization of a Primarily Mineral Calcium Phosphate-Poly (ε-caprolactone) Biocomposite
Vaidyanathan et al. Resorbable Polymer‐Ceramic Composites for Orthopedic Scaffold Applications

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION